

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

THIS PAGE BLANK (USPTO)

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 9/48	A1	(11) International Publication Number: WO 96/28542 (43) International Publication Date: 19 September 1996 (19.09.96)
(21) International Application Number: PCT/DK96/00104 (22) International Filing Date: 15 March 1996 (15.03.96) (30) Priority Data: 0262/95 16 March 1995 (16.03.95) DK (71) Applicant (for all designated States except US): NOVO NORDISK A/S [DK/DK]; Novo Allé, DK-2880 Bagsværd (DK). (72) Inventors; and (75) Inventors/Applicants (for US only): KAUPPINEN, Sakari [FI/DK]; Novo Nordisk a/s, Novo Allé, DK-2880 Bagsværd (DK). SI, Joan, Qi [DK/DK]; Novo Nordisk a/s, Novo Allé, DK-2880 Bagsværd (DK). SPENDLER, Tina [DK/DK]; Novo Nordisk a/s, Novo Allé, DK-2880 Bagsværd (DK). DAMBMANN, Claus [DK/DK]; Novo Nordisk a/s, Novo Allé, DK-2880 Bagsværd (DK). HALKIER, Torben [DK/DK]; Novo Nordisk a/s, Novo Allé, DK-2880 Bagsværd (DK). ØSTERGAARD, Peter, Rahbek [DK/DK]; Novo Nordisk a/s, Novo Allé, DK-2880 Bagsværd (DK). (74) Common Representative: NOVO NORDISK A/S; Corporate Patents, Novo Allé, DK-2880 Bagsværd (DK).		(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: AN ENZYME WITH AMINOPEPTIDASE ACTIVITY (57) Abstract The invention relates to a 35 kDa enzyme exhibiting aminopeptidase activity which is derived from a fungal microorganism, a DNA construct comprising a DNA sequence encoding said enzyme, a recombinant expression vector comprising said DNA construct, and a cell comprising said DNA sequence. It is also an object of the invention to provide a method for producing said enzyme exhibiting aminopeptidase activity, and an enzyme preparation comprising said enzyme, a bread-improving or dough-improving composition comprising the aminopeptidase of the invention. Finally the invention relates to the use of said enzyme exhibiting aminopeptidase activity or enzyme preparations or compositions thereof.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

Title: An enzyme with aminopeptidase activity

FIELD OF THE INVENTION

The present invention relates to an enzyme exhibiting
5 aminopeptidase activity, a method for producing said enzyme,
an enzyme preparation containing said enzyme exhibiting
aminopeptidase activity, and use of said enzyme for various
industrial purposes.

10

BACKGROUND OF THE INVENTION

Protein hydrolysates are being used in numerous food prod-
ucts. Traditionally protein hydrolysates were produced by
acid hydrolysis, but today enzymatic hydrolysis is regarded
15 as an attractive alternative.

One of the main problems of protein hydrolysates is that they
often taste bitter. When using e.g. soy protein or casein,
which are rich in hydrophobic L-amino acids, as the protein
20 source, the protein hydrolysate tends to have bitter taste.
In general it is believed that whether the taste of proteins
is bitter or not depends on the average hydrophobicity of the
L-amino acid residues, such as valine, leucine, isoleucine,
phenylalanine, tyrosine and tryptophan.

25

A vast number of enzymes exhibiting peptidase activity are
capable of performing enzymatic hydrolysis on vegetable,
yeast and/or animal proteins, resulting in highly nutritious
protein hydrolysates useful as food additives in products
30 such as soups, sauces, gravies, paste, tofu, bouillon,
seasonings, baby formulas, snacks, ready-to-eat meals etc.

Peptidases

All peptidases or proteases are hydrolases which act on proteins or its partial hydrolysate to decompose the peptide bond.

5

EP 427,385 (The Japanese R & D Association) discloses a genomic gene encoding an alkaline protease derived from yellow molds such as *Aspergillus oryzae*.

10 JP-0-2002374 and JP-0-2002375 (Shokuhin), describes an alkaline protease derived from *Aspergillus oryzae* for use in medicine, food, and detergents.

SU-891777 (Khark) concerns a microbial protease from *Asper-*
15 *gillus oryzae*, which can be used in food, medicine etc.

JP-5-4035283 (Ajinomoto KK) discloses preparation of enzymes from e.g. *Aspergillus oryzae* exhibiting endopeptidase activity, which can hydrolyse proteins almost completely.

20

WO 94/25580 (Novo Nordisk A/S) describes a method for hydrolysing vegetable or animal protein by incubating with a proteolytic enzyme preparation derived from a strain of *Aspergillus oryzae*.

25

Aminopeptidases

A subgroup of peptidases (proteases) are called aminopeptidases and are classified under the Enzyme Classification number E.C. 3.4.11 (aminopeptidases) in accordance
30 with the Recommendations (1992) of the International Union of Biochemistry and Molecular Biology (IUBMB)).

Aminopeptidases are capable of removing one or more amino terminal residues from polypeptides.

35

JP-7-5034631 (Noda) discloses a leucine aminopeptidase derived from yellow koji mold, which includes *Aspergillus oryzae*.

5 JP-7-4021798 (Zaidan Hojin Noda Sangyo) describes the production of miso by adding of a leucine aminopeptidase II prepared by cultivating a number of molds, including *Aspergillus oryzae* strain 460 and strain IAM 2616.

10 Van Heeke et al., Bioch. Biophys. Acta, (1992), 1131, 337-340, have disclosed the cloning of a 30 kDa aminopeptidase from the bacteria *Vibrio proteolyticus* deposited at the American Type Culture Collection under the ATCC No. 15338.

15 *Aspergillus oryzae* 460 is known to produce a number of leucine aminopeptidases. The molecular weight of three of these was calculated to 26,500, 56,000 and 61,000, respectively determined by gel filtration (Nakada et al., Agr. Biol. Chem, (1972), 37(4), 757-765; Nakada et al., Agr. Biol. Chem, (1972), 37(4), 767-774; Nakada et al., Agr. Biol. Chem, (1972), 37(4), 775-782). The *Aspergillus oryzae* 460 strain is deposited at the American Type Culture Collection as *A. oryzae* (ATTC no. 20386).

Reduction of bitter taste of protein hydrolysates

25 EP 65,663 and EP 325,986 (Miles Inc.) concerns enzymatic hydrolysis of proteins using a mixture of enzymes containing *Aspergillus oryzae* derived proteases. The obtained protein hydrolysate has a bland, non-bitter taste.

30 JP-4-7029577 (Asahi Electro-chemical Co.) concerns a protease, derived from *Aspergillus oryzae*, which does not produce any bitter component when decomposing protein.

Prior art discloses a plethora of enzymes exhibiting
35 peptidase, aminopeptidase and other enzyme activities. Said enzymes may be derived from a number of microorganisms, including the fungus species *Aspergillus oryzae*.

In general products, useful for producing protein hydrolysates without a bitter taste, comprise a mixture of peptidase and aminopeptidase activities.

5 It would therefore be desirable to be able to provide a single-component enzyme (i.e. substantially without any side activity) exhibiting only an activity useful for reducing the bitterness of protein hydrolysates used in food products.

10

BRIEF DESCRIPTION OF THE DRAWING

Figure 1 shows the result of SDS-PAGE analysis of supernatant from the *Aspergillus oryzae* A01568 35 kDa aminopeptidase
15 producing transformant.

SUMMARY OF THE INVENTION

20 The object of the present invention is to provide a single-component enzyme exhibiting an activity, which is particularly useful for preparing improving bread products and for producing proteins and/or protein hydrolysates without bitter taste for foodstuff.

25

The present inventors have surprisingly succeeded in isolating a DNA sequence encoding an enzyme exhibiting aminopeptidase activity, which advantageously may be used for improving the flavour, crust colour, crumb structure and dough sticki-
30 ness of baked products. Further, said novel enzyme is useful for producing protein or protein hydrolysates without bitter taste.

The complete DNA sequence encoding said aminopeptidase makes it possible to prepare single-component aminopeptidases.

35

The complete DNA sequence, shown in SEQ ID no. 1, encoding the aminopeptidase of the invention has, comprised in a

plasmid, been transformed into the bacteria strain *Escherichia coli* DSM no. 9965. This will be described further below.

5 By a database alignment search it was found that the DNA sequence shown in SEQ ID No. 1 is novel. The highest degree of similarity and identity was found to be 53 % and 32 %, respectively, to the above mentioned 30 kDa aminopeptidase from the bacteria *Vibrio proteolyticus* (ATCC No. 15338).

10

The inventors have characterized the precursor-form of the aminopeptidase consisting of a secretion signal and the 35 kDa aminopeptidase. The molecular weight (M_w) of the precursor-form was calculated to 41 kDa, and the isoelectric point (pI) was estimated to be approximately 4.9. Further, the amino acid composition of the aminopeptidase was estimated as shown in Table 1.

Table 1

20	Non-polar:	No.	Percent
	Ala	37	9.79
	Val	23	6.08
	Leu	29	7.67
25	Ile	20	5.29
	Pro	14	3.70
	Met	3	0.79
	Phe	19	5.03
	Trp	2	0.53
30	Polar:	No.	Percent
	Gly	28	7.41
	Ser	32	8.47
	Thr	25	6.61
35	Cys	4	1.06
	Tyr	13	3.44
	Asn	11	2.91
	Gln	16	4.23
40	Acidic:	No.	Percent
	Asp	29	7.67
	Glu	25	6.61
45	Basic:	No.	Percent
	Lys	28	7.41
	Arg	9	2.38
	His	10	2.65

The deduced complete precursor-form of the amino acid sequence of the 35 kDa enzyme is shown in SEQ ID No. 2.

Accordingly, the first aspect of the invention relates to an enzyme exhibiting aminopeptidase activity having an apparent molecular weight (M_w) of about 35 kDa determined by SDS-PAGE.

5 Mass spectrometry showed that the average mass of the recombinant aminopeptidase is in the range from 33 kDa to 35 kDa. The isoelectric point (pI) of the enzyme was determined to be about 4.9.

10 The isoelectric point, pI, is defined as the pH value where the enzyme molecule complex (with optionally attached metal or other ions) is neutral, i.e. the sum of electrostatic charges (net electrostatic charge, NEC) on the complex is equal to zero. In this sum of course consideration of the
15 positive or negative nature of the electrostatic charge must be taken into account.

In the following the terms "35 kDa aminopeptidase" and "the enzyme exhibiting aminopeptidase activity" are used
20 interchangeably for the single-component enzyme of the present invention.

The enzyme exhibiting aminopeptidase activity of the invention may be derived from a number of microorganisms. The
25 present inventors have isolated the aminopeptidase of the invention from the filamentous fungus *Aspergillus oryzae* A01568, which is a strain deposited at the American Type Culture Collection as *Aspergillus oryzae* 460 (FERM-P no. 1149, ATCC no. 20386, and further described in US patent no.
30 3,914,436.

The enzyme exhibiting aminopeptidase activity of the invention comprises at least one of the partial amino acid sequences shown in SEQ ID Nos. 6, 7, 8, 9, and 10,
35 respectively. SEQ ID No 11 is a peptide (5) which overlaps and extends the N-terminal sequence.

In the second aspect, the invention relates to a DNA construct comprising a DNA sequence encoding said aminopeptidase, which DNA sequence comprises

- 5 a) the aminopeptidase encoding part of the DNA sequence shown in SEQ ID No. 1, and/or the DNA sequence obtainable from *E. coli* DSM 9965, or
- b) an analogue of the DNA sequence shown defined in a), which
- 10 i) is homologous with the DNA sequence shown in SEQ ID No. 1 and/or the DNA sequence obtainable from *E. coli* DSM 9965, or
- 15 ii) hybridizes with the same oligonucleotide probe as the DNA sequence shown in SEQ ID No. 1 and/or the DNA sequence obtainable from *E. coli* DSM 9965, or
- 20 iii) encodes a polypeptide which is homologous with the polypeptide encoded by a DNA sequence comprising the DNA sequence shown in SEQ ID No. 1 and/or the DNA sequence obtainable from *E. coli* DSM 9965, or
- 25 iv) encodes a polypeptide which is immunologically reactive with an antibody raised against the purified aminopeptidase encoded by the DNA sequence shown in SEQ ID No 1 derived from *Aspergillus oryzae* A01568 or obtainable from *E. coli*, DSM. 9965.
- 30

In the present context, the "analogue" of the DNA sequence shown in SEQ ID No. 1 and/or the DNA sequence obtainable from *E. coli* DSM 9965, is intended to indicate any DNA sequence encoding an enzyme exhibiting aminopeptidase activity, which

35 has at least one of the properties i)-iv).

The analogous DNA sequence

- may be isolated from another or related (e.g. the same) organism producing the enzyme exhibiting aminopeptidase activity on the basis of any of the DNA sequences shown in 5 SEQ ID Nos. 3-5, e.g. using the procedures described herein, and thus, e.g. be an allelic or species variant of the DNA sequence comprising the DNA sequences shown herein,

- may be constructed on the basis of any of the DNA sequences 10 shown in SEQ ID Nos. 3-5, e.g. by introduction of nucleotide substitutions which do not give rise to another amino acid sequence of the aminopeptidase encoded by the DNA sequence, but which correspond to the codon usage of the host organism intended for production of the enzyme, or by introduction of 15 nucleotide substitutions which may give rise to a different amino acid sequence. However, in the latter case amino acid changes are preferably of a minor nature, that is conservative amino acid substitutions that do not significantly affect the folding or activity of the polypeptide, small 20 deletions, typically of one to about 30 amino acids; small amino- or carboxyl-terminal extensions, such as an amino-terminal methionine residue, a small linker peptide of up to about 20-25 residues, or a small extension that facilitates purification, such as a poly-histidine tract, an antigenic epitope or 25 a binding domain. See in general Ford et al., (1991), Protein Expression and Purification 2, 95-107. Examples of conservative substitutions are within the group of basic amino acids (such as arginine, lysine, histidine), acidic amino acids (such as glutamic acid and aspartic acid), polar amino acids 30 (such as glutamine and asparagine), hydrophobic amino acids (such as leucine, isoleucine, valine), aromatic amino acids (such as phenylalanine, tryptophan, tyrosine) and small amino acids (such as glycine, alanine, serine, threonine, methionine).

35

It will be apparent to persons skilled in the art that such substitutions can be made outside the regions critical to the

function of the molecule and still result in an active enzyme. Amino acids essential to the activity of the polypeptide encoded by the DNA construct of the invention, and therefore preferably not subject to substitution, may be identified according to procedures known in the art, such as site-directed mutagenesis or alanine-scanning mutagenesis (Cunningham and Wells, (1989), Science 244, 1081-1085). In the latter technique mutations are introduced at every residue in the molecule, and the resulting mutant molecules are tested for biological (i.e. aminopeptidolytic) activity to identify amino acid residues that are critical to the activity of the molecule. Sites of substrate-enzyme interaction can also be determined by analysis of crystal structure as determined by such techniques as nuclear magnetic resonance, crystallography or photoaffinity labelling. See, for example, de Vos et al. (1992), Science 255, 306-312; Smith et al., (1992), J. Mol. Biol., 224, 899-904; Wlodaver et al., (1992), FEBS Lett., 309, 59-64.

It will be understood that the DNA sequences shown in SEQ ID Nos. 3-5 are sequences which may be used for isolating the entire DNA sequence encoding the aminopeptidase, e.g. the DNA sequence shown in SEQ ID No. 1 and/or the DNA sequence transformed into the deposited strain *E. coli* DSM 9965. The term "analogue" is intended to include said entire DNA sequence, which comprises one or more of the partial sequences shown in SEQ ID Nos. 3-5 or parts thereof. The amino acid sequence (as deduced from the DNA sequence shown in SEQ ID No. 1) is shown in SEQ ID No. 2.

30

The homology referred to in i) above is determined as the degree of identity between the two sequences indicating a derivation of the first sequence from the second. The homology may suitably be determined by means of computer programs known in the art such as GAP provided in the GCG program package (Needleman, S.B. and Wunsch, C.D., (1970), Journal of Molecular Biology, 48, p. 443-453). Using GAP with

the following settings for DNA sequence comparison: GAP creation penalty of 5.0 and GAP extension penalty of 0.3, the coding region of the DNA sequence exhibits a degree of identity preferably of at least at least 70%, preferably at least 80%, especially at least 90%, with the coding region of the DNA sequence shown in SEQ ID No. 1 or the DNA sequence obtainable from the plasmid in *E. coli* DSM 9965.

The hybridization referred to in ii) above is intended to indicate that the analogous DNA sequence hybridizes to the same probe as the DNA sequence encoding the aminopeptidase under certain specified conditions which are described in detail in the Materials and Methods section hereinafter.

Normally, the analogous DNA sequence is highly homologous to the DNA sequence such as at least 60% homologous to the DNA sequence shown in SEQ ID No. 1 or the DNA sequence obtainable from the plasmid in *E. coli* DSM 9965 encoding an aminopeptidase of the invention, such as at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90% or even at least 95% homologous to said DNA sequence.

The homology referred to in iii) above is determined as the degree of identity between the two sequences indicating a derivation of the first sequence from the second. The homology may suitably be determined by means of computer programs known in the art such as GAP provided in the GCG program package (Needleman, S.B. and Wunsch, C.D., (1970), *Journal of Molecular Biology*, 48, p. 443-453). Using GAP with the following settings for DNA sequence comparison: GAP creation penalty of 5.0 and GAP extension penalty of 0.3, the coding region of the DNA sequence exhibits a degree of identity preferably of at least at least 70%, preferably at least 80%, especially at least 90%, with the coding region of the DNA sequence shown in SEQ ID No. 1 or the DNA sequence obtainable from the plasmid in *E. coli* DSM 9965.

The term "derived from" in connection with property iv) above is intended not only to indicate an aminopeptidase produced by strain A01568, but also an aminopeptidase encoded by a DNA sequence isolated from strain A01568 and produced in a host
5 organism transformed with said DNA sequence. The immunological reactivity may be determined by the method described in the "Materials and Methods" section below.

In further aspects the invention relates to an expression
10 vector harbouring a DNA construct of the invention, a cell comprising the DNA construct or expression vector and a method of producing an enzyme exhibiting aminopeptidase activity which method comprises culturing said cell under conditions permitting the production of the enzyme, and
15 recovering the enzyme from the culture.

It is also an object of the invention to provide an enzyme preparation enriched with the 35 kDa aminopeptidase of the invention.

20 Further, the invention provides a bread-improving or a dough-improving composition comprising an enzyme exhibiting aminopeptidase activity of the invention. Said composition may be combined with other enzymes, such as amylolytic enzymes, and conventional bread improving agents.

25

In a still further aspect the invention relates to a method for preparing a baked product and frozen dough comprising the 35 kDa aminopeptidase of the invention.

30 Finally the invention relates to the use of the 35 kDa aminopeptidase of the invention. The enzyme of the invention or a composition of the invention comprising such an enzyme may be used for improving the flavour, crust colour and crumb structure of baked products and to improve the stickiness of
35 frozen dough. The aminopeptidase of the invention may furthermore be used advantageously in connection with producing proteins and protein hydrolysates without bitter taste and

may be used for a number of purposes including, degradation or modification of protein containing substances; cleaning of contact lenses, preparation of food and animal feed etc.

5 DETAILED DESCRIPTION OF THE INVENTION

The DNA sequence of the invention encoding an enzyme exhibiting aminopeptidase activity may be isolated by a general method involving

- cloning, in suitable vectors, a DNA library from
10 *Aspergillus oryzae*,
- transforming suitable yeast host cells with said vectors,
- culturing the host cells under suitable conditions to express any enzyme of interest encoded by a clone in the DNA library,
- 15 - screening for positive clones by determining any aminopeptidase activity of the enzyme produced by such clones, and
- isolating the DNA coding an enzyme from such clones.

20 The general method is further disclosed in WO 93/11249 the contents of which are hereby incorporated by reference. A more detailed description of the screening method is given in Example 3 below.

25 Microbial Sources

The DNA sequence coding for the aminopeptidase of the invention may for instance be isolated by screening a cDNA library of the donor organism, and selecting for clones expressing the appropriate enzyme activity (i.e. aminopeptidase activity
30 as defined by the ability of the enzyme to hydrolyse Leucine-7 amido-4-methylcoumarin). The appropriate DNA sequence may then be isolated from the clone by standard procedures, e.g. as described in Example 1.

35 The donor organism may be a fungus of the *Aspergillus oryzae* (ATCC no. 20386) described in US patent no. 3,914,436

The complete full length DNA sequence encoding the aminopeptidase of the invention has been transformed into a strain of the bacteria *E. coli*, comprised in the expression plasmid pYES 2.0 (Invitrogen). Said bacteria has been deposited by the inventors according to the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure at the Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH., Mascheroder Weg 1b, D-38124 Braunschweig Federal Republic of Germany, (DSM).

Deposit date : 11.05.95
Depositor's ref. : NN49001
DSM designation : *E. coli* DSM No. 9965

15

Being an International Depository Authority under the Budapest Treaty, Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH., affords permanence of the deposit in accordance with the rules and regulations of said treaty, vide in particular Rule 9. Access to the two deposits will be available during the pendency of this patent application to one determined by the Commissioner of the United States Patent and Trademark Office to be entitled thereto under 37 C.F.R. Par. 1.14 and 35 U.S.C. Par. 122. Also, the above mentioned deposits fulfil the requirements of European patent applications relating to micro-organisms according to Rule 28 EPC.

The above mentioned deposit represents a substantially pure culture of the isolated bacteria. The deposit is available as required by foreign patent laws in countries wherein counterparts of the subject application, or its progeny are filed. However, it should be understood that the availability of the deposited strain does not constitute a license to practice the subject invention in derogation of patent rights granted by governmental action.

The DNA sequence encoding the enzyme exhibiting aminopeptidase activity can for instance be isolated from the above mentioned deposited strain by standard methods.

5 It is expected that a DNA sequence coding for a homologous enzyme, i.e. an analogous DNA sequence, is obtainable from other microorganisms. For instance, the DNA sequence may be derived by similarly screening a cDNA library of another microorganism, in particular a fungus, such as a strain of an
10 *Aspergillus* sp., in particular a strain of *A. aculeatus* or *A. niger*, a strain of another *Trichoderma* sp., in particular a strain of *T. reesei*, *T. viride*, *T. longibrachiatum* or *T. koningii* or a strain of a *Fusarium* sp., in particular a strain of *F. oxysporum*, or a strain of a *Humicola* sp.

15

Alternatively, the DNA sequence coding for an enzyme exhibiting aminopeptidase activity of the invention may, in accordance with well-known procedures, conveniently be isolated from DNA from a suitable source, such as any of the above
20 mentioned organisms, by use of synthetic oligonucleotide probes prepared on the basis of a DNA sequence disclosed herein. For instance, a suitable oligonucleotide probe may be prepared on the basis of any of the nucleotide sequences shown in SEQ ID Nos. 3-5 or the amino acid sequence shown in
25 SEQ ID No. 2 or any suitable subsequence thereof.

The DNA sequence may subsequently be inserted into a recombinant expression vector. This may be any vector which may conveniently be subjected to recombinant DNA procedures, and
30 the choice of vector will often depend on the host cell into which it is to be introduced. Thus, the vector may be an autonomously replicating vector, i.e. a vector which exists as an extrachromosomal entity, the replication of which is independent of chromosomal replication, e.g. a plasmid.
35 Alternatively, the vector may be one which, when introduced into a host cell, is integrated into the host cell genome and

replicated together with the chromosome(s) into which it has been integrated.

In the vector, the DNA sequence encoding the aminopeptidase should be operably connected to a suitable promoter and terminator sequence. The promoter may be any DNA sequence which shows transcriptional activity in the host cell of choice and may be derived from genes encoding proteins either homologous or heterologous to the host cell. The procedures used to ligate the DNA sequences coding for the aminopeptidase, the promoter and the terminator, respectively, and to insert them into suitable vectors are well known to persons skilled in the art (cf., for instance, Sambrook et al., (1989), Molecular Cloning. A Laboratory Manual, Cold Spring Harbor, NY).

The host cell which is transformed with the DNA sequence encoding the enzyme of the invention is preferably an eukaryotic cell, in particular a fungal cell such as a yeast or filamentous fungal cell. In particular, the cell may belong to a species of *Aspergillus*, most preferably *Aspergillus oryzae* or *Aspergillus niger*. Fungal cells may be transformed by a process involving protoplast formation and transformation of the protoplasts followed by regeneration of the cell wall in a manner known per se. The use of *Aspergillus* as a host microorganism is described in EP 238 023 (Novo Nordisk A/S), the contents of which are hereby incorporated by reference. The host cell may also be a yeast cell, e.g. a strain of *Saccharomyces*, in particular *Saccharomyces cerevisiae*, *Saccharomyces kluyveri* or *Saccharomyces uvarum*, a strain of *Schizosaccharomyces* sp., such as *Schizosaccharomyces pombe*, a strain of *Hansenula* sp. *Pichia* sp., *Yarrowia* sp. such as *Yarrowia lipolytica*, or *Kluyveromyces* sp. such as *Kluyveromyces lactis*.

35

A method of producing an enzyme of the invention

In a still further aspect, the present invention relates to a method of producing an enzyme according to the invention, wherein a suitable host cell transformed with a DNA sequence encoding the enzyme is cultured under conditions permitting
5 the production of the enzyme, and the resulting enzyme is recovered from the culture.

The medium used to culture the transformed host cells may be any conventional medium suitable for growing the host cells
10 in question. The expressed aminopeptidase may conveniently be secreted into the culture medium and may be recovered therefrom by well-known procedures including separating the cells from the medium by centrifugation or filtration, precipitating proteinaceous components of the medium by means of a salt
15 such as ammonium sulphate, followed by chromatographic procedures such as ion exchange chromatography, affinity chromatography, or the like.

Enzyme preparation

20 In a still further aspect, the present invention relates to an enzyme preparation useful for reducing the bitterness of proteins and/or protein hydrolysates for foodstuff.

The enzyme preparation, having been enriched with an enzyme
25 of the invention, may e.g. be an enzyme preparation comprising multiple enzymatic activities, such as an enzyme preparation comprising multiple enzymes for producing protein hydrolysates. The preparation to be enriched can be Flavourzyme® (available from Novo Nordisk A/S). Flavourzyme®
30 is a protease/peptidase complex derived from *Aspergillus oryzae* developed for hydrolysis of proteins.

Dependent on the use for which the enzyme preparation is to be used the aminopeptidase of the invention may be combined
35 with other enzyme as mentioned below.

In the present context, the term "enriched" is intended to indicate that the aminopeptidase activity of the enzyme preparation has been increased, e.g. with an enrichment factor of at least 1.1, preferable between 1.1 and 10, more 5 preferred between 2 and 8, especially between 4 and 6, conveniently due to addition of an enzyme of the invention prepared by the method described above.

Alternatively, the enzyme preparation enriched with an enzyme 10 exhibiting aminopeptidase activity may be one which comprises an enzyme of the invention as the major enzymatic component, e.g. a single-component enzyme preparation.

The enzyme preparation may be prepared in accordance with 15 methods known in the art and may be in the form of a liquid or a dry preparation. For instance, the enzyme preparation may be in the form of a granulate or a microgranulate. The enzyme to be included in the preparation may be stabilized in accordance with methods known in the art.

20

In another aspect the invention relates to a bread-improving or a dough-improving composition comprising an aminopeptidase of the invention. Said composition may further comprise enzymes selected from the group including amylolytic enzyme, 25 such as α -amylase, β -amylase, maltogenic α -amylase, amyloglucosidase, acid stable amylase, and 1,6-pullulanase.

Such enzymes are available from Novo Nordisk A/S as AMG™ (amyloglucosidase) obtained from a strain of *Aspergillus* 30 *niger*, Fungamyl™ (fungal amylase) obtained from a strain of *Aspergillus oryzae*, Novamyl™ (maltogenic amylase) obtained from a strain of *Bacillus stearothermophilus*.

The composition of the invention may also comprise one or 35 more additional enzymes. Examples of such enzymes include a cellulase, a hemicellulase, a pentosanase (useful for the partial hydrolysis of pentosans which increases the extensi-

bility of the dough), a lipase (useful for modification of lipids present in the dough or dough constituents so as to soften the dough), a peroxidase (useful for improving the dough consistency), an oxidase, e.g. a glucose oxidase, a laccase, a xylanase, a protease (useful for gluten weakening, in particular when using hard wheat flour).

The other enzyme components are preferably of microbial origin and may be obtained by conventional techniques used in the art as mentioned above.

The enzyme(s) to be used in the present invention may be in any form suited for the use in question, e.g. in the form of a dry powder or granulate, in particular a non-dusting granulate, a liquid, in particular a stabilized liquid, or a protected enzyme. Granulates may be produced, e.g. as disclosed in US 4,106,991 and US 4,661,452 (both to Novo Industri A/S), and may optionally be coated by methods known in the art. Liquid enzyme preparations may, for instance, be stabilized by adding nutritionally acceptable stabilizers such as a sugar, a sugar alcohol or another polyol, lactic acid or another organic acid according to established methods. Protected enzymes may be prepared according to the method disclosed in EP 238,216.

25

Normally, for inclusion in pre-mixes or flour it is advantageous that the enzyme(s) is/are in the form of a dry product, e.g. a non-dusting granulate, whereas for inclusion together with a liquid it is advantageously in a liquid form.

30

In addition or in an alternative to other enzyme components, the dough-improving and/or bread-improving composition may comprise a conventionally used baking agent, e.g. one or more of the following constituents:

A milk powder (providing crust colour), gluten (to improve the gas retention power of weak flours), an emulsifier (to improve dough extensibility and to some extent the consist-

ency of the resulting bread), granulated fat (for dough softening and consistency of bread), an oxidant (added to strengthen the gluten structure; e.g. ascorbic acid, potassium bromate, potassium iodate or ammonium persulfate), an amino acid (e.g. cysteine), a sugar, and salt (e.g. sodium chloride, calcium acetate, sodium sulfate or calcium sulphate serving to make the dough firmer), flour or starch. Such components may also be added directly to the dough in accordance with a method of the invention.

10

Examples of suitable emulsifiers are mono- or diglycerides, diacetyl tartaric acid esters of mono- or diglycerides, sugar esters of fatty acids, polyglycerol esters of fatty acids, lactic acid esters of monoglycerides, acetic acid esters of monoglycerides, polyoxyethylene stearates, phospholipids and lecithin.

The bread-improving and/or dough improving composition of the invention is typically included in the dough in an amount corresponding to 0.01-5%, in particular 0.1-3%.

In accordance with the method of the invention, in which an enzyme with aminopeptidase activity of the invention, optionally in combination with other enzymes as described above, is used for the preparation of dough and/or baked products, the enzyme(s) may be added as such to the mixture from which the dough is made or to any ingredient, e.g. flour, from which the dough is to be made. Alternatively, the enzyme(s) may be added as a constituent of a dough-improving and/or a bread-improving composition as described above, either to flour or other dough ingredients or directly to the mixture from which the dough is to be made.

The dosage of the enzyme(s) to be used in the method of the present invention should be adapted to the nature and composition of the dough in question as well as to the nature of the enzyme(s) to be used. Normally, the enzyme preparation is

added in an amount corresponding to 0.01-1000 mg enzyme protein per kg of flour, preferably 0.1-100 mg enzyme protein per kg of flour, more preferably 0.1-10 mg enzyme protein per kg of flour.

5

In terms of enzyme activity, the appropriate dosage of a given single component enzyme with aminopeptidase activity, optionally in combination with other enzyme(s), for exerting a desirable improvement of flour or crust colour of a baked
10 product will depend on the enzyme(s) and the enzyme substrate(s) in question. The optimal dosage may vary dependent on the flour or yeast types and baking process. The skilled person may determine a suitable enzyme unity dosage on the basis of methods known in the art.

15

However, according to the present invention the enzyme exhibiting aminopeptidase activity of the invention is added in an amount corresponding 30 to 1000 LAPU, preferably 50 to 500 LAPU, especially 80 to 300 LAPU, such as about 100 LAPU
20 per kg of flour. LAPU is defined below.

Amylolytic enzymes are normally added in from 1 to 50 FAU per kg flour. One FAU (Fungal α -Amylase Unit) is the amount of enzyme which breaks down 5.26 g starch (Merck, Amylum solu-
25 bile Erg. B.6, BACh 9947275) per hour using Novo Nordisk's standard method for determination of α amylase activity. A detailed description of Novo Nordisk's method (AF 216) of analysis is available on request.

Maltogenic amylase are normally added in from 1 to 1000 MANU
30 per kg flour (Maltogenic Amylase Novo Units). One MANU is defined as the amount of enzyme which, under standard conditions, hydrolyzes 1 micromole of maltotriose per minute. The analytic method (AF 203) is available on request.

35 When one or more additional enzyme activities are to be added in accordance with the method of the invention, these activities may be added separately or together with the singes

component enzyme with exopeptidase activity, optionally as constituent(s) of the bread-improving and/or dough-improving composition of the invention. The other enzyme activities may be any of the above described enzymes and may be dosed in accordance with established baking practice.

As mentioned above the enzyme exhibiting aminopeptidase activity, optionally in combination with other enzyme(s) as described above, is added to any mixture of dough ingredients, to the dough, or to any of the ingredients to be included in the dough, in other words the enzyme(s) may be added in any step of the dough preparation and may be added in one, two or more steps, where appropriate.

The handling of the dough and/or baking is performed in any suitable manner for the dough and/or baked product in question, typically including the steps of kneading the dough, subjecting the dough to one or more proofing treatments, and baking the product under suitable conditions, i.e. at a suitable temperature and for a sufficient period of time. For instance, the dough may be prepared by using a normal straight dough process, a sour dough process, an overnight dough method, a low-temperature and long-time fermentation method, a frozen dough method, the Chorleywood Bread process, or the Sponge and Dough process.

The dough and/or baked product prepared by the method of the invention are normally based on wheat meal or flour, optionally in combination with other types of meal or flour such as corn flour, rye meal, rye flour, oat flour or meal, soy flour, sorghum meal or flour, or potato meal or flour.

In the present context the term "baked product" is intended to include any product prepared from dough, either of a soft or a crisp character. Examples of baked products, whether of a white, light or dark type, which may advantageously be produced by the present invention are bread (in particular

white, whole-meal or rye bread), typically in the form of loaves or rolls, French baguette-type bread, pita bread, tacos, cakes, pan-cakes, biscuits, crisp bread and the like.

- 5 The dough of the invention may be of any of the types discussed above, and may be fresh or frozen.

The preparation of frozen dough is described by K. Kulp and K. Lorenz in "Frozen and Refrigerated Doughs and Batters".

- 10 When using the aminopeptidase of the invention for frozen bread the flavour, the crust colour and the crispiness are improved.

- From the above disclosure it will be apparent that the dough
15 of the invention is normally a leavened dough or a dough to be subjected to leavening. The dough may be leavened in various ways such as by adding sodium bicarbonate or the like or by adding a leaven (fermenting dough), but it is preferred to leaven the dough by adding a suitable yeast culture such
20 as a culture of *Saccharomyces cerevisiae* (baker's yeast). Any of the commercially available *S. cerevisiae* strains may be employed.

- As mentioned above, the present invention further relates to
25 a pre-mix, e.g., in the form of a flour composition, for dough and or baked products made from dough, which pre-mix comprises an enzyme exhibiting aminopeptidase activity of the invention and optionally other enzymes as specified above. The pre-mix may be prepared by mixing the relevant enzyme(s)
30 or a bread-improving and/or dough-improving composition of the invention comprising the enzyme(s) with a suitable carrier such as flour, starch, a sugar or a salt. The pre-mix may contain other dough-improving and/or bread-improving additives, e.g., any of the additives, including enzymes,
35 mentioned above.

Use of the 35 kDa Aminopeptidase of the invention

Use of the Enzyme of the invention for preparing Baked Products

The enzyme or an enzyme preparation of the invention may be used in baking, e.g. in order to weaken the gluten components of flour so as to obtain a softening of so-called hard flour.

However, it has surprisingly been found that the aminopeptidase of the invention does not degrade the network of the gluten which is normally observed when proteases are used for preparing baked products. Consequently, the dough characteristics and crumb structure are not affected.

Further, when adding the 35 kDa aminopeptidase of the invention to the dough or dough ingredients, when preparing baked products, the flavour crust colour and/or the crumb structure and/or the crust colour of a baked product will be substantially improved, as shown in Example 13.

Further, the enzyme of the invention improves the dough stickiness.

The addition of the enzyme of the invention results in baked products having a flavour of yeasty type, providing a "freshly baked" bread smell. This makes the invention of particular interest for the sponge-dough-system, in which an addition of the enzyme can reduce the sponge fermentation time without a concomitant loss of yeasty flavour, and in the no-time-dough process (most European processes), in which the enzyme can provide a yeasty flavour which is otherwise normally lacking products prepared from such processes.

Without being limited to any theory it is presently believed that further improved flavour and/or crust colour of a baked product may be obtained when a single component enzyme with exopeptidase activity is used in combination with an amylolytic enzyme, in particular an amylolytic enzyme which is

capable of liberating reducing sugar molecules from flour or other constituents of the dough. The increased amount of reducing sugars in the dough provides an increase in Maillard reactions taking place during baking thereby further improving the flavour and crust colour of the baked product.

Use of the Enzyme of the invention for Reducing Bitter Taste

The enzyme or enzyme preparation of the invention may be used for reducing the bitterness of proteins and/or protein hydrolysate for foodstuff.

Also contemplated according to the invention is the production of free amino acids from proteins and/or protein hydrolysates. In the case of the free amino acid are glutamine acid it enhances the flavour of food products.

Said protein or protein hydrolysate may be of animal or vegetable origin.

In an embodiment of the invention the protein to be hydrolysed is casein or soy protein.

The protein may be use for producing foodstuff such as cheese and foodstuff containing cocoa.

25

Even though the aminopeptidase and enzyme preparations enriched with an enzyme of the invention may be used especially advantageously in connection with producing proteins or protein hydrolysates without bitter taste, the aminopeptidase of the invention can be used for a number of industrial applications, including degradation or modification of protein containing substances, such cell walls. Some proteins, like extensins, are components of plant cell walls. Aminopeptidases will therefore facilitate the degradation or modification of plant cell walls.

The dosage of the enzyme preparation of the invention and other conditions under which the preparation is used may be determined on the basis of methods known in the art.

5 Extraction of Oil from Plants

The enzyme preparation according to the invention may be useful for extraction of oil from plant sources like olives and rape or for production of juice from different fruits like apples, pears and citrus. It may also be useful in the
10 wine industry, especially in the white wine industry, to prevent haze formation. Furthermore, it may be used to modify and degrade proteins, e.g. in order to reduce the viscosity caused or partially caused by proteins, or to facilitate fermentative processes where proteins are involved, or it may
15 be used to improve the digestibility of proteins and other nutrients.

The Use for preparing Food and Feed

The aminopeptidase preparation may also be used in the food
20 and feed industry to improve the digestibility of proteins. For instance, the enzyme or enzyme preparation may be added to animal feed or may be used to process animal feed, in particular feed for piglets or poultry.

25 Further the enzyme or enzyme preparation of the invention may be useful to make protein hydrolysates from, e.g., vegetable proteins like soy, pea, lupin or rape seed protein, milk like casein, meat proteins, or fish proteins. The aminopeptidase may be used for protein hydrolysates to improve the solubil-
30 ity, consistency or fermentability, to reduce antigenicity or for other purposes to make food, feed or medical products. The aminopeptidase may be used alone or together with other aminopeptidases or together with other enzymes like exopeptidases. The use of the aminopeptidase of the invention
35 together with exopeptidase rich enzyme preparations will improve the taste of the protein hydrolysates.

Furthermore, the enzyme or enzyme preparation may be used in the processing of fish or meat, e.g. to change texture and/or viscosity.

5 Use in Brewing processes

The enzyme preparation may also be used to facilitate fermentative processes, like yeast fermentation of barley, malt and other raw materials for the production of e.g. beer.

10

Use for making Protoplast

The enzyme preparation may be useful for making protoplasts from fungi.

15 Use for the production of Peptides

The enzyme preparation may be useful for production of peptides from proteins, where it is advantageous to use a cloned enzyme essentially free from other proteolytic activities.

20 Use for degradation of Proteins

Further, the aminopeptidase preparation can be used to degrade protein in order to facilitate purification of or to upgrade different products, like in purification or upgrading of gums, like guar gum, xanthan gum, degumming of silk, or

25 improvement of the quality of wool.

Use for cleaning Contact Lenses

Further the enzyme or enzyme preparation may be used for cleaning of contact lenses.

30

The invention is described in further detail in the following examples which are not in any way intended to limit the scope of the invention as claimed.

35

METHODS AND MATERIALS**Materials**

Donor organism: *Aspergillus oryzae* A01568 (described in US
5 patent no. 3,914,436)

Host organism:

Escherichia coli MC1061 (Meissner et al., (1987), Proc. Natl.
10 Acad. Sci. U.S.A., 84, 4171-4176: cDNA library strain

Saccharomyces cerevisiae W3124 (van den Hazel et al., (1992),
Eur. J. Biochem., 207, 277-283): Activity screening strain.
15

Schizosaccharomyces pombe: Bröker et al., (1989), FEBS
Letters, 248, 105-110.

Other organisms:

20

Aspergillus oryzae A1560 (Christensen et al. (1988),
Bio/technology 6, 1419-1422).

Plasmids:

25 pYES 2.0: Transformation vector (Invitrogen).

pHD414: *Aspergillus* expression vector is a derivative of the
plasmid p775 (described in EP 238.023). The construction of
the pHD414 is further described in WO 93/11249. pHD414
30 contains the *A. niger* glucoamylase terminator and the *A.*
oryzae TAKA amylase promoter.

pHD423 is a derivative of pHD414 (described in WO 94/20611)
with a new polylinker.

35

pUC18: Expression vector (Sambrook et al., (1989), Molecular Cloning: A Laboratory Manual, 2. ed.; Cold Spring Harbor Laboratory, Cold Spring Harbor, New York)

5 pC1EXP3: plasmid comprising the 1.4 kb cDNA insert encoding the 35 kDa aminopeptidase of the invention. (See Example 3 and SEQ ID NO 1)

pC1EXP4: plasmid comprising a cDNA sequence, which is 120 bp
10 shorter than the pC1EXP3 1.4 kb cDNA insert. (see Example 10 and SEQ ID NO 12)

p3SR2: *A. nidulans* amdS+ gene carrying plasmid (Christensen et al., (1988), Bio/Technology 6, 1419-1422)

15

pP1: yeast expression vector, which is an *E. coli*/*S. pombe* shuttle vector containing the ADH promoter and URA 3 as selective marker (Bröcker et al., (1989), FEBS Letters, 248, 105-110).

20

Primers:

Universal pUC primers (Sambrook et al., (1989), supra)

Deduced primer sequences used in PCR reactions

25 s2:

5'- GAR ACI GTI CAR AAY CTI AT -3'

s3:

5'- GAY AAR AAR AAY TTY GAW ACI GT -3'

30

as1:

5' - TCI ACR TTR TCI GTI ATI ATY TCI AT -3'

35 (s=sense, as= anti-sense)

A = Adenine

G = Guanine

C = Cytosine

T = Thymine

40 I = Deoxyinosine

Y = C or T

R = A or G

W = A or T

5 Forward and Reverse pYES primers (Invitrogen)

Enzymes:

Lysine-specific protease

Novozym® 234 (Novo Nordisk A/S)

10 Alcalase® (Novo Nordisk A/S)

Neutrase® (Novo Nordisk A/S)

Peptides of the 35 kDa aminopeptidase:

(see SEQ ID No. 6-11)

15 N-terminal:

Direct N-terminal sequencing of authentic and recombinant aminopeptidase revealed the same N-terminal amino acid sequence for the two enzymes showing that the recombinant enzyme is proteolytically processed identical to the authentic enzyme. The N-terminal sequence found was

Tyr-Pro-Asp-Ser-Val-Gln-His-Xaa-Glu-Thr-Val-Gln-Asn-Leu-Ile-
s2 ----->

25 Lys-Ser-Leu-Asp-Lys-Lys-Asn-Phe-Glu-Thr-Val-Leu-Gln-Pro-
s3 ----->

(Xaa is a glycosylated Asn-residue)

30 The following peptide sequence was obtained from peptides derived from a S-carboxymethylated sample of the aminopeptidase by cleavage with a lysyl-specific protease.

Peptide 1:

35

Tyr-Pro-Asp-Ser-Val-Gln-His-Xaa-Glu-Thr-Val-Gln-Asn-Leu-Ile-Lys

40 Peptide 2:

Gly-Val-Thr-Val-Glu-Pro-Phe-Lys

Peptide 3:

Val-Ile-Val-Asp-Ala-Tyr-Cys-Thr-Ile-Pro-Thr-Val-Asp-Ser-Lys

5

Peptide 4:

Gly-Thr-Thr-Asp-Ala-Gly-Lys-Pro-Glu-Ser-Ile- Glu-Ile-Ile-Thr-
 <-----as1

10 Asp-Asn-Val-Asp-Glu-Asn-Leu-Thr-Lys

Peptide 5

15 Asn-Phe-Glu-Thr-Val-Leu-Gln-Pro-Phe-Ser-Glu-Phe-His-Asn-Arg-
Tyr-Tyr-Lys

(Overlaps and extends the N-terminal sequence).

20

Media and other materials:

STC: 1.2 M sorbitol, 10 mM Tris-HCl, pH = 7.5., 10 mM CaCl₂
BSA (Sigma, type H25)

25 Leucine-7 amido-4-methylcoumarin (Sigma)

PEG 4000 (polyethylene glycol, molecular weight = 4,000)
(BDH, England)

Sequenase®Kit (United Stated Biochemical, USA)

Hybond-N nylon membrane (Amersham, USA)

30 Q-sepharose (Pharmacia Tm)

Superdex 200 Tm

Amicon membrane

VG Analytical TofSpec

35 α -Cyano-4-hydroxycinnamic acid (Aldrich, Steinheim, Germany).

YPD: 10 g yeast extract, 20 g peptone, H₂O to 810 ml. Autoclaved, 90 ml 20% glucose (sterile filtered) added.

40 10 x Basal salt: 66.8 g yeast nitrogen base, 100 g succinic acid, 60 g NaOH, H₂O ad 1000 ml, sterile filtered.

SC-URA: 90 ml 10 x Basal salt, 22.5 ml 20% casamino acids, 9 ml 1% tryptophan, H₂O ad 806 ml, autoclaved, 3.6 ml 5% threonine and 90 ml 20% glucose or 20% galactose added.

5 SC-H broth: 7.5 g/l yeast nitrogen base without amino acids, 11.3 g/l succinic acid, 6.8 g/l NaOH, 5.6 g/l casamino acids without vitamins, 0.1 g/l tryptophan. Autoclaved for 20 min. at 121°C. After autoclaving, 10 ml of a 30% galactose solution, 5 ml of a 30% glucose solution and 0.4 ml of a 5% threonine solution were added per 100 ml medium.

SC-H agar: 7.5 g/l yeast nitrogen base without amino acids, 11.3 g/l succinic acid, 6.8 g/l NaOH, 5.6 g/l casamino acids without vitamins, 0.1 g/l tryptophan, and 20 g/l agar
15 (Bacto). Autoclaved for 20 min. at 121°C. After autoclaving, 55 ml of a 22% galactose solution and 1.8 ml of a 5% threonine solution were added per 450 ml agar.

YNB-1 agar: 3.3 g/l KH₂PO₄, 16.7 g/l agar, pH adjusted to 7.
20 Autoclaved for 20 min. at 121°C. After autoclaving, 25 ml of a 13.6% yeast nitrogen base without amino acids, 25 ml of a 40% glucose solution, 1.5 ml of a 1% L-leucine solution and 1.5 ml of a 1% histidine solution were added per 450 ml agar.

25 YNB-1 broth: Composition as YNB-1 agar, but without the agar.

Minimal plates: (Cove Biochem. Biophys. Acta 113 (1966) 51-56) containing 1.0 M sucrose, pH 7.0, 10 mM acetamide as nitrogen source and 20 mM CsCl

30

Whey protein hydrolysate: Whey hydrolysed with Alcalase® and Neutrase® was diluted with water until the protein content was 8% (w/w) of the total solution.

35 Methods

RNA isolation: The total RNA was prepared, from frozen, powdered mycelium of *A. oryzae* A01568, by extraction with

guanidinium thiocyanate followed by ultracentrifugation through a 5.7 M CsCl cushion (Chirgwin et al., (1979), *Biochemistry* 18, 5294-5299). The poly(A)⁺RNA was performed by oligo(dT)-cellulose affinity chromatography (Aviv, H, and Leder, P., (1972), *Proc. Natl. Acad. Sci. U.S.A.* 69, 1408-1412).

cDNA synthesis: Double-stranded cDNA was synthesized from 5 µg of *Aspergillus oryzae* poly(A)⁺ RNA as described by Kofod et al., *J. of Biol. Chem.*, (1994), 269, 29182-29189, except that 25 ng of random hexanucleotide primers (Pharmacia, Sweden) were included in the first strand synthesis.

Construction of cDNA library:

The cDNA library was constructed as described by Kofod et al., *J. of Biol. Chem.*, (1994), 269, 29182-29189.

Transformation of *Saccharomyces cerevisiae*:

To ensure that all the bacterial clones were tested in yeast, a number of yeast transformants 5 times larger than the number of bacterial clones in the original pools was set as the limit.

One µl aliquots of purified plasmid DNA (100 ng/µl) from individual pools were electroporated (200 Ω, 1.5 kV, 24 µF) into 40 µl of competent *S. cerevisiae* cells (OD600 = 1.5 in 500 ml YPD, washed twice in cold distilled water, once in cold 1 M sorbitol, resuspended in 0.5 ml 1 M sorbitol, Becker & Guarante, 1991). After addition of 1 ml 1 M cold sorbitol, 80 µl aliquots were plated on SC + glucose - uracil to give 250-400 c.f.u./plate and incubated at 30°C for 3-5 days.

Transformation of *Schizosaccharomyces pombe*

Schizosaccharomyces pombe was transformed as described by Bröcker, (1987) *BioTechniques*, 5, 51-517.

Purification of 35 kDa aminopeptidase from *Aspergillus oryzae*:

One gram freeze dried powder of the fermentation supernatant of *Aspergillus oryzae* A01568 was dissolved in 100 ml Tris-acetate buffer (25 mM pH 8). Ionic strength was 2 mSi. The suspension was filtered through 45 μ millipore filter. The filtered solution was applied on a 200 ml anion exchange chromatography column packed with Q-sepharose, which was equilibrated with the Tris-acetate buffer. Alkaline protease 10 which is a major endoprotease with isoelectric point of 8 was collected in effluent. The column was washed with the Tris-acetate buffer until no more UV absorbing material was present in effluent.

The bound proteins were eluted with linear salt gradient 15 using 0 to 0.5 M NaCl in the Tris-acetate buffer (pH 8) using 10 column volume with a flow rate of 4 ml/minutes. Fractions containing aminopeptidase activity (see below) were pooled and dialyzed against Tris-acetate buffer (25 mM , pH 6).

20

The dialyzed pool containing activity was adjusted to pH 6 and ionic strength to 2 mSi and applied on 50 ml High performance Q-sepharose column, equilibrated with 25 mM Tris-acetate buffer pH 6, for anion exchange chromatography. The 25 column was then washed until the UV absorbing material in effluent was under 0.05 at 280 nm. Bound activity was then eluted with 20 column volume linear salt gradient, from 0 to 0.5 M NaCl at a flow rate of 2 ml/minutes. Fractions containing aminopeptidase activity were pooled and concentrated by 30 ultrafiltration, using 50 mM sodium-acetate buffer (pH 6).

Two ml of the concentrated pool containing aminopeptidase activity was applied on Superdex 200 Tm column equilibrated with 50 mM sodium acetate buffer (pH 6) containing 0.1 M 35 NaCl. The gel filtration was carried out using a flow rate of 0.5 ml/minutes. Samples containing aminopeptidase activity

were pooled and concentrated by ultrafiltration using Amicon membrane with a cut-off-value of 10 kDa.

**Amino acid sequence determination of N-terminal and internal
5 peptides of the *Aspergillus oryzae* aminopeptidase:**

S-carboxymethylated samples of the purified native aminopeptidase is digested with lysyl-specific protease, and the resulting peptides are separated by reverse phase high pressure liquid chromatography (HPLC) and sequenced as
10 described by Matsudaira, A Practical Guide to Protein and peptide Purification for Microsequencing, 3-88, Academic Press Inc, San Diego, CA, in an Applied Biosystems 473A sequencer according to the manufacturer's instructions (Applied Biosystems).

15

Reagents and solvents for amino acid sequencing are from Applied Biosystems (Foster City, CA).

20 Designing of PCR primers:

The PCR primers were designed as described by Kofod et al., J. of Biol. Chem., (1994), 269, 29182-29189.

Generation of a cDNA probe for an aminopeptidase using PCR:

25 One μ g of double stranded plasmid DNA from a cDNA library pool was PCR amplified using 500 pmol of each of the designed primers in combinations with 500 pmol of pYES 2.0 polylinker primer (forward and reverse), a DNA thermal cycler (Landgraf, Germany) and 2.5 units of *Taq* polymerase (Perkin-Elmer).

30

Thirty cycles of PCR were performed using a cycle profile of denaturation at 94°C for 1 minute, annealing at 55°C for 2 minutes, and extension at 72°C for 3 minutes.

Dideoxy chain-termination method:

The method was carried out as described by Sanger et al., (1977), Proc. Natl. Acad. Sci. U.S.A. 74, 5463-5467, using the Sequenase®Kit and universal pUC primers.

5

Characterization of positive cDNA clones by Southern blot analysis:

The positive clones were characterized by the use of Southern blot hybridization using the 0.5 kb random-primed ³²P-labelled PCR-product or 35 kDa aminopeptidase as probe. The hybridizations were carried out in 2 x SSC, 5 x Denhardt's solution, 0.5% (w/v) SDS, 100 µg/ml denatured salmon sperm DNA for 48 hours at 65°C followed by washing at high stringency in 2 x SSC (2 x 15 minutes), 2 x SSC, 0.5% SDS (30 minutes), 0.2 x SSC, 0.5% SDS (30 minutes) and finally in 2 x SSC (15 minutes), at 65°C (Sambrook et al. (1989), supra).

Electrophoresis

Electrophoresis was performed on a 0.7% agarose gel from SeaKem, FMC.

Capillary blotting

Capillary blotting method is described by Sambrook et al., (1989), supra) using 10 x SSC as transfer buffer

25

High stringency washes of hybridized clones:

Washing was carried out in 2 x 15 minutes in 2 x SSC, 2 x 30 minutes in 0.1 x SSC, 0.5% SDS and 15 minutes in 2 x SSC, at 65°C.

30

Transformation of *Aspergillus oryzae*:

Transformation of *Aspergillus oryzae* was carried out as described by Christensen et al., (1988), Biotechnology 6, 1419-1422.

35

Construction of the aminopeptidase expression cassette for *Aspergillus*

Plasmid DNA was isolated from the positive *E. coli* clones using standard procedures and analyzed by restriction enzyme analysis. The cDNA insert was excised using appropriate restriction enzymes and ligated into an *Aspergillus* expression vector.

Transformation of *Aspergillus oryzae* or *Aspergillus niger*

10 (general procedure)

100 ml of YPD (Sherman et al., Methods in Yeast Genetics, Cold Spring Harbor Laboratory, 1981) is inoculated with spores of *A. oryzae* or *A. niger* and incubated with shaking at 37°C for about 2 days. The mycelium is harvested by filtration through miracloth and washed with 200 ml of 0.6 M MgSO₄. The mycelium is suspended in 15 ml of 1.2 M MgSO₄. 10 mM NaH₂PO₄, pH = 5.8. The suspension is cooled on ice and 1 ml of buffer containing 120 mg of Novozym® 234 is added. After 5 minutes 1 ml of 12 mg/ml BSA is added and incubation with gentle agitation continued for 1.5-2.5 hours at 37°C until a large number of protoplasts is visible in a sample inspected under the microscope.

The suspension is filtered through miracloth, the filtrate transferred to a sterile tube and overlaid with 5 ml of 0.6 M sorbitol, 100 mM Tris-HCl, pH = 7.0. Centrifugation is performed for 15 minutes at 100 g and the protoplasts are collected from the top of the MgSO₄ cushion. 2 volumes of STC are added to the protoplast suspension and the mixture is centrifuged for 5 minutes at 1000 g. The protoplast pellet is resuspended in 3 ml of STC and repelleted. This is repeated.

Finally the protoplasts are resuspended in 0.2-1 ml of STC.

100 µl of protoplast suspension is mixed with 5-25 µg of the appropriate DNA in 10 µl of STC. Protoplasts are mixed with p3SR2 (an *A. nidulans* amdS gene carrying plasmid). Th

mixture is left at room temperature for 25 minutes. 0.2 ml of 60% PEG 4000, 10 mM CaCl₂ and 10 mM Tris-HCl, pH 7.5 is added and carefully mixed (twice) and finally 0.85 ml of the same solution is added and carefully mixed. The mixture is left at room temperature for 25 minutes, spun at 2500 g for 15 minutes and the pellet is resuspended in 2 ml of 1.2 M sorbitol. After one more sedimentation the protoplasts are spread on the appropriate plates. Protoplasts are spread on minimal plates to inhibit background growth. After incubation for 4-7 days at 37°C spores are picked and spread for single colonies. This procedure is repeated and spores of a single colony after the second re-isolation is stored as a defined transformant.

15 Purification of the *Aspergillus oryzae* transformants:
Aspergillus oryzae colonies are purified through conidial spores on AmdS⁺-plates (+ 0,01% Triton X-100) and growth in YPM for 3 days at 30° C.

20 Identification of aminopeptidase positive *Aspergillus oryzae* transformants:

The supernatants from the *Aspergillus oryzae* transformants were assayed for aminopeptidase on agar plates overlaid with 60 µg/ml of Leucine-7 amido-4-methylcoumarin. Positive transformants were identified by analyzing the plates by fluorescence under UV-light after 5 minutes to 2 hours incubation at 30°C.

SDS-PAGE analysis:

30 SDS-PAGE analysis of supernatant from an *Aspergillus oryzae* aminopeptidase producing transformant. The transformant was grown in 5 ml YPM for three days. 10 µl of supernatant was applied to 12% SDS-polyacrylamide gel which was subsequently stained with Coomassie Brilliant Blue.

35 Mass spectrometry

Mass spectrometry is done using matrix assisted laser desorption ionisation time-of flight mass spectrometry in a

VG Analytical TofSpec. For mass spectrometry 2 μ l of sample is mixed with 2 μ l saturated matrix solution (α -cyano-4-hydroxycinnamic acid in 0.1% TFA:acetonitrile (70:30)) and 2 μ l of the mixture spotted onto the target plate. Before introduction into the mass spectrometer the solvent was removed by evaporation. Samples are desorbed and ionised by 4 ns laser pulses (337 nm) at threshold laser power and accelerated into the field-free flight tube by an accelerating voltage of 25 kV. Ions were detected by a micro channel plate set at 1850 V. The spectra is calibrated externally with proteins of known mass.

Immunological cross-reactivity:

Antibodies to be used in determining immunological cross-reactivity may be prepared by use of a purified aminopeptidase. More specifically, antiserum against the aminopeptidase of the invention may be raised by immunizing rabbits (or other rodents) according to the procedure described by N. Axelsen et al. in: A Manual of Quantitative Immuno-electrophoresis, Blackwell Scientific Publications, 1973, Chapter 23, or A. Johnstone and R. Thorpe, Immunochemistry in Practice, Blackwell Scientific Publications, 1982 (more specifically pp. 27-31). Purified immunoglobulins may be obtained from the antisera, for example by salt precipitation ((NH_4)₂ SO₄), followed by dialysis and ion exchange chromatography, e.g. on DEAE-Sephadex. Immunochemical characterization of proteins may be done either by Ouchterlony double-diffusion analysis (O. Ouchterlony in: Handbook of Experimental Immunology (D.M. Weir, Ed.), Blackwell Scientific Publications, 1967, pp. 655-706), by crossed immuno-electrophoresis (N. Axelsen et al., *supra*, Chapters 3 and 4), or by rocket immuno-electrophoresis (N. Axelsen et al., Chapter 2).

Southern blot analysis:

Genomic DNA from *A. oryzae* is isolated according to Yelton et al., (1984), Proc. Natl. Acad. Sci. U.S.A. 81., p. 1470-1474,

and digested to completion with BamHI, BglII, EcoRI and HindIII (10 µg/sample), fractionated on a 0.7 % agarose gel, denatured and blotted to a nylon filter (Hybond-N) using 10 x SSC as transfer buffer (Southern, E. M., (1975), J. Mol. Biol. 98, p. 503-517). The aminopeptidase cDNA is ³²P-labeled (> 1 x 10⁹ cpm/µg) by random-priming and used as a probe in Southern analysis. The hybridization and washing conditions are as described in RNA gel blot analysis. The filter is autoradiographed at -80°C for 12 hours.

10

RNA gel blot analysis:

Poly(A)⁺ RNA (1 µg) from *A. oryzae* is electrophoresed in 1.2 % agarose-2.2 M formaldehyde gels (Thomas, P. S., (1983) Methods Enzymol. 100, pp. 255-2663) and blotted to a nylon membrane (Hybond-N) with 10 x SSC as transfer buffer. The aminopeptidase cDNA is ³²P-labeled (> 1 x 10⁹ cpm/µg) by random priming and hybridized to the membrane for 18-20 hours at 65°C in 5 x SSC, 5 x Denhardt's solution, 0.5% SDS (w/v) and 100 µg/ml denatured salmon sperm DNA. The filter is washed in 5 x SSC at 65°C (2 x 15 minutes), 2 x SSC, 0.5 % SDS (1 x 30 minutes), 0.2 x SSC, 0.5 % SDS (1 x 30 minutes), and 5 x SSC (2 x 15 minutes). The filter is autoradiographed at - 80°C for 12 hours.

25 Determination of aminopeptidase activity (LAPU)

One LAPU is defined as the amount of enzyme which hydrolyzes 1 µmole of L-leucine-p-nitroanilide per minute using the method described in AF 298/1-GB (available on request from Novo Nordisk A/S).

30

% DH determination based on TMBS analysis

The extent of protein hydrolysis may be determined by the degree of hydrolysis achieved. In the context of this invention, the degree of hydrolysis (DH) is defined by the following formula:

$$DH = \frac{h}{h_{\infty}} \times 100 \%$$

h is the number of peptide bonds hydrolysed and h_0 is the total number of peptide bonds in the protein. h_0 is dependent on the type of raw material, whereas h can be expressed as a function of meqv leucine NH_2 , measured by for instance TNBS-5 analyses

Determination of %DH is described in EF-9415317 (available on request from Novo Nordisk A/S)

10 Testing of Doughs and Breads

According to the present invention the effect of adding a single component enzyme with aminopeptidase activity may be tested in doughs and breads by using the following method:

15 Preparation of Breads

Procedure:

1. Dough mixing (Spiral mixer)

3 min. at 700 RPM

20 5 min. at 1400 RPM

the mixing time is predetermined and adjusted by a skilled baker based on the flour used so as to obtain an optimum dough consistence under the testing conditions used.

2. 1st proof: 30°C - 80% RH, 15 min.

25 3. Scaling and shaping;

4. Resting for 5 minutes at ambient temperature;

5. Final proof: 32°C - 80% RH, 45 minutes for rolls, 55 minutes for bread;

6. Baking: 225°C, 22 minutes for rolls and 30 minutes for
30 loaf.

Evaluation of Dough and Baked Products

Dough and baked products may be evaluated as follows:

35

Loaf specific volume: the mean value of 4 loaves volume are measured using the traditional rape seed method. The specific

volume is calculated as volume ml per g bread. The specific volume of the control (without enzyme) is defined as 100. The relative specific volume index is calculated as:

$$\text{Specific vol. index} = \frac{\text{specific vol. of 4 loaves}}{\text{spec. vol. of 4 control loaves}} \times 100$$

The dough stickiness and crumb structure may be evaluated visually according to the following scale:

10

	<u>Dough stickiness:</u>	almost liquid	1
		too sticky	2
		sticky	3
		acceptable	3.5
		normal	4
15		dry	5

20

	<u>Crumb structure:</u>	very poor	1
		poor	2
		non-uniform	3
		uniform/good	4
		very good	5

Shock test: After the second proof a pan containing the dough is dropped from a height of 20 cm. The dough is baked and the volume of the resulting bread is determined.

Yeasty Flavour

30	as control	3
	slightly improved	3.5
	Improved	4

Crumb colour

The crumb colour is determined visually

35

EXAMPLES**Example 1**Construction of cDNA library

5 Total RNA was extracted from *Aspergillus oryzae* A01568. Poly(A)+RNA was isolated by oligo(dT)-cellulose affinity chromatography and double stranded cDNA (ds cDNA) was synthesized.

10 A cDNA library from *Aspergillus oryzae* A01568 consisting of 3.5×10^6 clones was constructed into the yeast expression vector pYES 2.0.

15 Example 2Amplification and characterization of cDNA clones.

The aminopeptidase was purified from *Aspergillus oryzae* A01568 as described above in the section "Materials and Methods".

20

A long NH₂-terminal sequence and four internal sequences (including Peptide 1 to 5) of the aminopeptidase were obtained by digestion of S-carboxymethylated purified protein with a lysyl-specific protease.

25

Based on these sequences three primers were synthesized (as1, s2 and s3, respectively). Double stranded cDNA (ds cDNA) was used as template in the PCR amplification experiment as described above in the section "Materials and Methods".

30

Analysis of the resulting PCR-products revealed a 0.5 kb fragment with one primer pair (primer s3 and primer as1).

The PCR-fragment was sub-cloned into SmaI-cut dephosphorylated pUC18 vector and sequenced from both ends using the Dideoxy chain-termination method as described above in the section "Material and Methods".

In addition to the primer encoded residues, the sequence of Peptide 2 obtained from the purified aminopeptidase, aligned with the deduced amino acid sequence, confirmed that the desired cDNA species had been specifically PCR amplified.

5

Example 3

Screening of the cDNA library for clones encoding the aminopeptidase from *Aspergillus oryzae*

Approximately 10,000 colonies from the cDNA library from
10 *Aspergillus oryzae* A01568 were screened by colony hybridization as described above. This yielded positive clones with inserts ranging from 650 bp to 1.5 kb.

The positive clones were analyzed by Southern blot analysis
15 as described above in the section "Materials and Methods".

Purified plasmid DNA (about 1 μ g) from the aminopeptidase cDNA clones was digested to completion by HindIII and XbaI to release the cDNA inserts from the pYES vector. The samples
20 were electrophoresed and transferred to a Hybond-N nylon membrane by the capillary blotting method. The filters were washed at high stringency resulting in positive clones with inserts ranging from 900 bp to 1700 bp.

25 Strongly hybridizing clones were analyzed by sequencing the ends of the cDNAs with forward and reverse pYES primers.

Analysis of the sequence data showed that some of these clones were truncated cDNAs whereas others appeared to be
30 full-length clones. The nucleotide sequence and deduced amino acid sequence of one of the full-length clones (pClEXP3) obtained (shown in figure 1) contains a cDNA insert of 1.4 kb.

Exempl 4Expression of the aminopeptidase in *Aspergillus oryzae*

To obtain high level production of aminopeptidase in *Aspergillus oryzae*, the cDNA insert from the pC1EXP3 clone was
5 sub-cloned into pHD423 and co-transformed with the AmdS⁺ plasmid into *Aspergillus oryzae* as described above.

The 1.4 kb cDNA insert from pC1EXP3 was isolated from pYES
2.0 by Hind III and Not I digestion, ligated to a Not I/Hind
10 III cleaved pHD 423 vector, and transformed into *E. coli*.

The resulting transformants were purified twice (see above)
and assayed for aminopeptidase activity as described above.
Transformant pA3EXP3/1 showed detectable aminopeptidase
15 activity.

Example 5Expression level of aminopeptidase producing transformant (pA3EXP3/1)

20 The amount and purity (level of expression) of secreted aminopeptidase from the transformant (pA3EXP3/1) was determined semi-quantitatively by SDS-PAGE using the non-transformed *A. oryzae* strain A01560 as a negative control and the *A. oryzae* A01568 strain as positive control (see figure 1).

25

A 36-37 kDa polypeptide could be seen in pA3EXP3/1, not present in the negative control. The size of the recombinant aminopeptidase is approximately 2 kDa higher than that of the native aminopeptidase (a double band of about 35 kDa),
30 possibly due to additional glycosylation or other types of post-translational modifications.

Example 6

Mass spectrometry showed that the recombinant aminopeptidase
35 is glycosylated as the mass determined exceed the mass of the polypeptide calculated from the cDNA sequence to be 32.4 kDa.

The average mass of the recombinant aminopeptidase is 34.1 kDa with the masses ranging from 33 kDa to 35 kDa.

The apparent molecular weight (M_w) determined by SDS-PAGE (as described in "Materials and Methods" was found to be about 35 kDa.

Example 7

Fermentation of 35 kDa aminopeptidase producing transformant

10 The *Aspergillus oryzae* transformant pA3EXP3/1 was grown in one liter shake flasks containing 150 ml DAP 2C (pH = 5.9) for three days at 30°C.

The amount of secreted aminopeptidase was estimated by SDS-
15 PAGE analysis to approximately 0.5 g/liter supernatant.

Example 8

Expression of 35 kDa aminopeptidase clones in *S. pombe*

The full-length 35 kDa aminopeptidase cDNA clone pC1EXP3 was re-transformed into *Schizosaccharomyces pombe* by electropora-
20 tion. The 1.4 kb cDNA insert was released from the pYES 2.0 vector by SpeI and NotI digestion and subcloned into the SpeI/NotI cleaved yeast expression vector pP1, which is an *E. coli/S. pombe* shuttle vector containing the ADH promoter, and assayed for aminopeptidase activity.

25

It was shown that one *S. pombe* transformant had strong aminopeptidase activity, indicating that *S. pombe* is able to synthesize and secrete a functionally active 35 kDa aminopeptidase from *Aspergillus oryzae* A01568.

30

Example 9

Organization and Expression of the Aminopeptidase gene

The copy number of the aminopeptidase gene in the *A. oryzae* A01568 genome was determined by Southern blot hybridization
35 described in the "Materials and Methods" section. Total DNA isolated from *A. oryzae* was digested to completion with BamHI, BglII, EcoRI or HindIII and hybridized with the aminopeptida-

se cDNA. The aminopeptidase probe detects only single strongly hybridizing fragments in each case except in BamHI digestion, which gives two hybridizing fragments due to a BamHI site at nucleotide position 640. This indicates that the 5 aminopeptidase gene is present as a single copy in the *A. oryzae* A01568 genome.

Example 10

To study the expression of the 35 kDa aminopeptidase gene, 10 poly (A)⁺ RNA extracted from *A. oryzae* A01568 mycelium was subjected to Northern blot analysis. Probing of the blotted RNA with the aminopeptidase cDNA revealed two species of mRNA of approximately 1.45 and 1.55 kilobases. These two mRNAs do not appear to represent transcripts of two distinct genes 15 since the same pattern of hybridization was observed when the filters were washed at high stringency. The difference in size of the two mRNAs could be due to different lengths of 3' untranslated region, because of two polyadenylation sites, in accordance with the two cDNA species isolated from the 20 *Aspergillus oryzae* cDNA library, one corresponding to clones pClEXP3 and another one corresponding to pClEXP4, which is 120 bp shorter. Both mRNAs encode the same aminopeptidase.

25 Example 11

Removing bitter taste from whey protein hydrolysate

The fermentation broth of *Aspergillus oryzae* transformant pA3EXP3/1 was tested for the ability to debitter a solution containing 8% (w/w) protease hydrolysed whey protein.

30

The aminopeptidase activity of fermentation broth was 5.58 LAPU/g.

The substrate protein solution was tested in flasks containing 100 g of the 8% protein hydrolysate. The fermentation 35 broth exhibiting aminopeptidase activity was added until the relationship between enzyme and substrate (E/S) was 0.25%,

calculated on the basis of a product with 5000 LAPU/g (equivalent to 12.5 LAPU/g protein), and was then re-hydrolysed for 6 hours at 50°C, pH 7.0.

- 5 The pH and the osmolarity was determined (using standard methods) after 1 minute and 6 hours, respectively. % DH was determined using the TNBS-method (described above) and % FAA (% free amino acids) was determined using standard methods.

10	Aminopeptidase	pH after 1 minute	pH after 6 hours	Increase mOsm	% DH by TNBS-method	total % FAA
	Transformant	6.47	6.65	59	7.01*	13
	Blind	6.61	6.81	1		3

* the increase of DH caused by the hydrolysis of the substrate by the aminopeptidase.

- 15 DH of the blind is 28 %

A sample of debittered hydrolysate containing 13 % FFA was analyzed for the content of leucine. It was found that leucine constituted about 2.7%. while leucine constituted 20 about 0.3% of the blind.

Example 12

Taste test

The taste of debittered protein hydrolysate was assessed by a 25 tasting panel of 5 persons using a Bitterness Index (BI) between 0 (not bitter) and 10 (blind).

The bitterness, of a sample of bitter tasting 3.5 % protein hydrolysate (blind) and a similar sample subjected to the 30 transformant, was assessed.

The Bitterness Index (BI) for the protein hydrolysate sample subjected to the transformant was found to be in the range of about 6.2.

This result shows that the 35 kDa aminopeptidase had debittered the protein hydrolysate samples.

Example 13

5 Bread flavour, dough stickiness and crumb structure

The flavour, dough stickiness and crumb structure of bread prepared using from 0 to 300 LAPU per kg flour were compared with bread prepared using the commercial product Flavourzyme®. The bread were prepared and assessed as
10 described above in the "Material and Methods" section.

The following result (average of duplication) were found:

15

Enzyme(s)	LAPU/kg flour	Avg. vol. Index	Flavour	Dough stickiness	Crumb structure
Flavourzyme®	80	112	4	3	crumby and open
Enzyme of the invention	0	100	3	4	as control
	10	100	3	4	as control
	30	100	3	4	as control
	50	100	3.25	4	as control
	80	98	3.5	4	as control
	100	102	3.5	4	as control
	150	97	4	4	as control
	200	99	4	4	as control
	300	100	4	4	as control

20 As can be seen from the above table the 35 kDa aminopeptidase of the invention gives a significant flavour enhancement in the form of a "fresh baked" bread smell when added in amounts from 30 to 300 LAPU per kg flour. The crumb structure is not affected by the aminopeptidase of the invention. The dough

stickiness is improved in comparison to the commercial protease/peptidase complex Flavourzyme®.

As will be apparent to those skilled in the art in the light
5 of the foregoing disclosure, many alterations and modifications are possible in the practice of this invention without departing from the spirit or scope thereof. Accordingly, the scope of the invention is to be construed in accordance with the substance defined by the claims below.

SEQUENCE LISTING

5 (1) GENERAL INFORMATION:

(i) APPLICANT:

- 10 (A) NAME: Novo Nordisk A/S
 (B) STREET: Novo Alle
 (C) CITY: Bagsvaerd
 (E) COUNTRY: Denmark
 (F) POSTAL CODE (ZIP): DK-2880
 (G) TELEPHONE: +45 4444 8888
 (H) TELEFAX: +45 4449 3256

15 (ii) TITLE OF INVENTION: An enzyme with aminopeptidase activity

(iii) NUMBER OF SEQUENCES: 12

20 (iv) COMPUTER READABLE FORM:

- (A) MEDIUM TYPE: Floppy disk
 (B) COMPUTER: IBM PC compatible
 (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 (D) SOFTWARE: Patent In Release #1.0, Version #1.30B (EPO)

25

(2) INFORMATION FOR SEQ ID NO: 1:

(i) SEQUENCE CHARACTERISTICS:

- 30 (A) LENGTH: 1409 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

35 (ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

- (B) STRAIN: *Aspergillus oryzae* A01568

40 (ix) FEATURE:

- (A) NAME/KEY: CDS
 (B) LOCATION: 52..1183

45 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

CGAGCATTCC	GTTCGGATTC	ACTTGGTGGT	ACAGCCTTTC	GTTCCTCTCA	G	ATG	CGT	57									
							Met Arg										
							1										
50	TTC	CTC	CCC	TGC	ATC	GCG	ACT	TIG	GCA	GCC	AGG	GCC	TCT	GCC	CCT	GCT	105
	Phe	Leu	Pro	Cys	Ile	Ala	Thr	Leu	Ala	Ala	Thr	Ala	Ser	Ala	Leu	Ala	
			5				10						15				
55	ATT	GGA	GAC	CAT	GTA	GCC	TGG	GAC	GAT	CAG	TAT	GTC	CAT	GAA	CTC	GCC	153

	Ile Gly Asp His Val Arg Ser Asp Asp Gln Tyr Val Leu Glu Leu Ala	
	20 25 30	
	CCG GGA CAA ACG AAA GGT GIG ACG GAA GCA GAG AAA TGG GCT CTG AGA	201
5	Pro Gly Gln Thr Lys Val Val Thr Glu Ala Glu Lys Trp Ala Leu Arg	
	35 40 45 50	
	GCT GAG GGC AAG GGT TTC TTC GAT ATA ACC GAA CCG GGC AGT ACC CTG	249
10	Ala Glu Gly Lys Arg Phe Phe Asp Ile Thr Glu Arg Ala Ser Ser Leu	
	55 60 65	
	GAA CTC GCA TCG AAC AAG AAA CAA AAG CTC CCG GGT ACC TAC CCC GAT	297
	Glu Leu Ala Ser Asn Lys Lys Gln Lys Leu Ala Val Thr Tyr Pro Asp	
	70 75 80	
15	TTC GIG CAA CAC AAC GAG ACC GIG CAA AAT CTG ATC AAG TCG CTC GAC	345
	Ser Val Gln His Asn Glu Thr Val Gln Asn Leu Ile Lys Ser Leu Asp	
	85 90 95	
20	AAA AAG AAC TTC GAA ACC GGT CTC CAG CCG TTC TCG GAG TTC CAC AAT	393
	Lys Lys Asn Phe Glu Thr Val Leu Gln Pro Phe Ser Glu Phe His Asn	
	100 105 110	
	CGC TAT TAC AAG AGC GAC AAT GGC AAG AAA TCA TCC GAG TGG CTG CAA	441
25	Arg Tyr Tyr Lys Ser Asp Asn Gly Lys Lys Ser Ser Glu Trp Leu Gln	
	115 120 125 130	
	GGC AAG ATT CAG GAA ATC ATC TCC GGC AGT GGA GCA AAG GGA GTC ACT	489
30	Gly Lys Ile Gln Glu Ile Ile Ser Ala Ser Gly Ala Lys Gly Val Thr	
	135 140 145	
	GIG GAG CCT TTC AAA CAC TCC TTC CCG CAG TCG AGT CTG ATT GCG AAA	537
	Val Glu Pro Phe Lys His Ser Phe Pro Gln Ser Ser Leu Ile Ala Lys	
	150 155 160	
35	ATC CCC GGC AAG AGT GAC AAG ACC ATC GIG CTT GGA GCG CAT CAG GAC	585
	Ile Pro Gly Lys Ser Asp Lys Thr Ile Val Leu Gly Ala His Gln Asp	
	165 170 175	
40	TCC ATC AAC CTT GAT TCA CCC TCA GAG GGC GGT GCA CCG GGA GCT GAT	633
	Ser Ile Asn Leu Asp Ser Pro Ser Glu Gly Arg Ala Pro Gly Ala Asp	
	180 185 190	
	GAC GAT GCA TCC GGC GGT GGT ACC ATT CTC GAA GGC TTC CCG GGT CTC	681
45	Asp Asp Gly Ser Gly Val Val Thr Ile Leu Glu Ala Phe Arg Val Leu	
	195 200 205 210	
	CTG ACG GAC GAG AAG GTC GCA GGC GGT GAG GCT CCG AAC ACC GGT GAG	729
50	Leu Thr Asp Glu Lys Val Ala Ala Gly Glu Ala Pro Asn Thr Val Glu	
	215 220 225	
	TTC CAC TTC TAT GGC GCA GAG GAG GGT GGT CTG CTG GCA AGT CAG GAC	777
	Phe His Phe Tyr Ala Gly Glu Glu Gly Gly Leu Leu Gly Ser Gln Asp	
	230 235 240	
55		

52

	ATC TTC GAG CAG TAC TCG CAG AAA ACC CGA GAC GIG AAA GCC ATG CTT Ile Phe Glu Gln Tyr Ser Gln Lys Ser Arg Asp Val Lys Ala Met Leu 245 250 255	825
5	CAA CAG GAT ATG ACG GGT TAT ACT AAA GGC ACA ACC GAT GCT CGA AAG Gln Gln Asp Met Thr Gly Tyr Thr Lys Gly Thr Thr Asp Ala Gly Lys 260 265 270	873
10	CCG GAG TCG ATC GGT ATC ATC ACT GAC AAT GTC GAT GAG AAC CIG ACC Pro Glu Ser Ile Gly Ile Ile Thr Asp Asn Val Asp Glu Asn Leu Thr 275 280 285 290	921
15	AAG TTC CIG AAG GTC ATT GTC GAT GCT TAT TGC ACT ATC CCG ACC GTC Lys Phe Leu Lys Val Ile Val Asp Ala Tyr Cys Thr Ile Pro Thr Val 295 300 305	969
20	GAT TCG AAA TGC CGA TAC CGA TGC TCT GAC CAT GCT TCT GGC ACG AAG Asp Ser Lys Cys Gly Tyr Gly Cys Ser Asp His Ala Ser Ala Thr Lys 310 315 320	1017
	TAT GGT TAT CCC GGC GCA TTC GCA TTC GAG TCA GGC TTT GGC GAC GAC Tyr Gly Tyr Pro Ala Ala Phe Ala Phe Glu Ser Ala Phe Gly Asp Asp 325 330 335	1065
25	ACC CCT TAC ATT CAC TCG GCT GAT GAT ACG ATT GAG ACC GTC AAC TTT Ser Pro Tyr Ile His Ser Ala Asp Asp Thr Ile Glu Thr Val Asn Phe 340 345 350	1113
30	GAC CAT GIG CIG CAA CAC GGC AAA CIG ACT CIT CGA TTT GCA TAT GAG Asp His Val Leu Gln His Gly Lys Leu Thr Leu Gly Phe Ala Tyr Glu 355 360 365 370	1161
35	CIT GCC TTC GCA GAT TCG CIG T AAGGCTTATG ACGAGGTTG TTATAGGAG Leu Ala Phe Ala Asp Ser Leu 375	1213
	AGATCAGTC CACAGTGTG TATATATGT GGGGGGGT TCAATAGCA CTTGATTTA	1273
40	GGAGTGTGTT AGCTTTGGTG GGTAAATGG AGGCGAAT CTAAGCAACA TCGACTGGA GGCTGTGAGG GGGGCTTAC AAGAGTTTT GAGCTACTA AGGAGATA AAGTCAGAA	1333
	AAAAAAAA AAAAAA	1393
45		1409

(2) INFORMATION FOR SEQ ID NO: 2:

(i) SEQUENCE CHARACTERISTICS:

- 50 (A) LENGTH: 377 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

55

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

Met Arg Phe Leu Pro Cys Ile Ala Thr Leu Ala Ala Thr Ala Ser Ala
 1 5 10 15
 5 Leu Ala Ile Gly Asp His Val Arg Ser Asp Asp Gln Tyr Val Leu Glu
 20 25 30
 Leu Ala Pro Gly Gln Thr Lys Val Val Thr Glu Ala Glu Lys Trp Ala
 10 35 40 45
 Leu Arg Ala Glu Gly Lys Arg Phe Phe Asp Ile Thr Glu Arg Ala Ser
 50 55 60
 15 Ser Leu Glu Leu Ala Ser Asn Lys Lys Gln Lys Leu Ala Val Thr Tyr
 65 70 75 80
 Pro Asp Ser Val Gln His Asn Glu Thr Val Gln Asn Leu Ile Lys Ser
 85 90 95
 20 Leu Asp Lys Lys Asn Phe Glu Thr Val Leu Gln Pro Phe Ser Glu Phe
 100 105 110
 His Asn Arg Tyr Tyr Lys Ser Asp Asn Gly Lys Lys Ser Ser Glu Trp
 25 115 120 125
 Leu Gln Gly Lys Ile Gln Glu Ile Ile Ser Ala Ser Gly Ala Lys Gly
 130 135 140
 30 Val Thr Val Glu Pro Phe Lys His Ser Phe Pro Gln Ser Ser Leu Ile
 145 150 155 160
 Ala Lys Ile Pro Gly Lys Ser Asp Lys Thr Ile Val Leu Gly Ala His
 165 170 175
 35 Gln Asp Ser Ile Asn Leu Asp Ser Pro Ser Glu Gly Arg Ala Pro Gly
 180 185 190
 Ala Asp Asp Asp Gly Ser Gly Val Val Thr Ile Leu Glu Ala Phe Arg
 40 195 200 205
 Val Leu Leu Thr Asp Glu Lys Val Ala Ala Gly Glu Ala Pro Asn Thr
 210 215 220
 45 Val Glu Phe His Phe Tyr Ala Gly Glu Glu Gly Gly Leu Leu Gly Ser
 225 230 235 240
 Gln Asp Ile Phe Glu Gln Tyr Ser Gln Lys Ser Arg Asp Val Lys Ala
 245 250 255
 50 Met Leu Gln Gln Asp Met Thr Gly Tyr Thr Lys Gly Thr Thr Asp Ala
 260 265 270
 Gly Lys Pro Glu Ser Ile Gly Ile Ile Thr Asp Asn Val Asp Glu Asn
 55 275 280 285

54

Leu Thr Lys Phe Leu Lys Val Ile Val Asp Ala Tyr Cys Thr Ile Pro
 290 295 300
 Thr Val Asp Ser Lys Cys Gly Tyr Gly Cys Ser Asp His Ala Ser Ala
 5 305 310 315 320
 Thr Lys Tyr Gly Tyr Pro Ala Ala Phe Ala Phe Glu Ser Ala Phe Gly
 325 330 335
 10 Asp Asp Ser Pro Tyr Ile His Ser Ala Asp Asp Thr Ile Glu Thr Val
 340 345 350
 Asn Phe Asp His Val Leu Gln His Gly Lys Leu Thr Leu Gly Phe Ala
 355 360 365
 15 Tyr Glu Leu Ala Phe Ala Asp Ser Leu
 370 375

20

(2) INFORMATION FOR SEQ ID NO: 3:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 26 base pairs
 25 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Primer
 30

(iii) HYPOTHEICAL: NO

(iv) ANTI-SENSE: YES

35 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

TCTACTTCT CIGTATATAT YTCAT

26

40 (2) INFORMATION FOR SEQ ID NO: 4:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 20 base pairs
 45 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Primer

50 (iii) HYPOTHEICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

55

55

CARACTIGTIC ARAAYCTTAT

20

5 (2) INFORMATION FOR SEQ ID NO: 5:

(i) SEQUENCE CHARACTERISTICS:

- 10 (A) LENGTH: 23 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Primer

15 (iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

GAYAARAARA AYTTCAGAC IGT

23

25 (2) INFORMATION FOR SEQ ID NO: 6:

(i) SEQUENCE CHARACTERISTICS:

- 30 (A) LENGTH: 16 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

35 (iii) HYPOTHETICAL: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

40 Tyr Pro Asp Ser Val Gln His Xaa Glu Thr Val Gln Asn Leu Ile Lys
 1 5 10 15

45 (2) INFORMATION FOR SEQ ID NO: 7:

(i) SEQUENCE CHARACTERISTICS:

- 50 (A) LENGTH: 8 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

55 (iii) HYPOTHETICAL: NO

56

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

5 Gly Val Thr Val Glu Pro Phe Lys
1 5

(2) INFORMATION FOR SEQ ID NO: 8:

10

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 15 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

15

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

20

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

25 Val Ile Val Asp Ala Tyr Cys Thr Ile Pro Thr Val Asp Ser Lys
1 5 10 15

(2) INFORMATION FOR SEQ ID NO: 9:

30

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 24 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

35

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

40

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:

45 Gly Thr Thr Asp Ala Gly Lys Pro Glu Ser Ile Glu Ile Ile Thr Asp
1 5 10 15

Asn Val Asp Glu Asn Leu Thr Lys
20

50

(2) INFORMATION FOR SEQ ID NO: 10:

55

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 29 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

5

(ii) MOLECULE TYPE: peptide

(iii) **HYPOTHETICAL: NO**

10

(v) FRAGMENT TYPE: N-terminal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:

15

Tyr Pro Asp Ser Val Gln His Xaa Glu Thr Val Gln Asn Leu Ile Lys
1 5 10 15

Ser Leu Asp Lys Lys Asn Phe Glu Thr Val Leu Gln Pro
20 25

20

(2) INFORMATION FOR SEQ ID NO: 11:

25

(i) **SEQUENCE CHARACTERISTICS:**

(A) LENGTH: 18 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

30

(ii) MOLECULE TYPE: peptide

(iii) **HYPOTHETICAL: NO**

35

(v) FRAGMENT TYPE: N-terminal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:

Asn Phe Glu Thr Val Leu Gln Pro Phe Ser Glu Phe His Asn Arg Tyr Tyr Lys
40 1 5 10 15

(2) INFORMATION FOR SEQ ID NO: 12

45

(i) **SEQUENCE CHARACTERISTICS:**

(A) LENGTH: 1272 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

50

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(B) STRAIN: *Aspergillus oryzae* A01568

55

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:


	CCTGAGCGTT CGGTGGGAT GCACTGGG GTCAGCGTT TGGTCTCTC AGATGGGTT	60
5	TCTTCCCTG CTTGGGACT TTGGAGCA CGGCTCTGC CCTTGCATT GGAGACGTC	120
	TACCTTCCA GGTACGAT GTCTAGAC TGGGCGGG ACAACGAA GTTGTCAGG	180
	AAGCGAGAA ATGGCTCTG AGGCTGAG GAGCGGTT CTTCGTTA ACGAAGGG	240
10	CGGTAGGCT GGAATGCA TGAACAAG ACAAAGCT CGGGTTAC TACCGGTT	300
	CGTGCACA CAGGAGAC GTGAAATC TGTACGTC GCTGACAA AAGACTTC	360
15	AAACGGTCT CAGCGGTC TGGAGTTC AATGCTA TTACAGAC GACATGGCA	420
	AGATATC CGATGGCT CAGGACA TTACGAAT CTCTCGCC AGTGGAGA	480
	AGGAGTAC TTGGAGCT TTCAACT CCTTCCCA GTGAGTCT ATTCGAAA	540
20	TCCCCGCA GATGACAG ACGTGGTC TTGGAGCA TGGGACTC ATCACTTC	600
	ATCACTTC AGAGCGGT GACCGGAG CTGATGCA TGGTCCGC GTTGTTACA	660
25	TTCTGAGC CTTCGGTT CTCTGAGC AGGAGAGT CGAGCGGT GAGCTCCA	720
	ACACGTTA GTTCACTT TATGCGGAG AGAGGGTG TCTCTGGA AGTACGCA	780
	TTCTGACA GTCTCGAG AAAGCGGAG AGTGAAAG CATGCTCA CAGGTTGA	840
30	CGGTATTAC TAAAGGCA ACGATGCT GAAAGCGA GTGATGCT ATCTACTC	900
	ACATGTGA TGAGACCT ACPAGTTC TGAGGTAT TTGATGCT TATGACTA	960
35	TCCGACGT GATTCGAA TCGGATAG GTGCTCTA CCGCTTCT GCGAGAGT	1020
	ATGGTTTC CGCGCTTC GATTCGAT CAGCTTTG GAGGAGAC CTTTACTC	1080
	ACTGCGTA TGTACGAT GACCGTCA ACTTGACA TTGCTGCA CAGGCAAC	1140
40	TGACTCTG ATTCGAT GAGCTGCT TCGATTC GCTGAGGC TTTCAGAC	1200
	GTGTGTGA GCGAGATC CAGTCACA GTGTGATA TATGGGCG CGGTTCAA	1260
45	TACACTTA AA	1272

59

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>13</u> , line <u>10-15</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution DEUTSCHE SAMMLUNG VON MIKROORGANISMEN UND ZELL- KULTUREN GmbH	
Address of depositary institution (including postal code and country) Mascheroder Weg 1b, D-38124 Braunschweig, Federal Re- public of Germany	
Date of deposit 11.05.95	Accession Number DSM No. 9965
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
<p>During the pendency of the patent application a sample of the deposited microorganism is only to be provided to an independent expert nominated by the person requesting the sample (cf. e.g. Rule 28(4) EPC / Regulation 3.25 of Australia Statutory Rules 1991 No 71) in those designated states providing for such "expert solution".</p>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

For receiving Office use only <input checked="" type="checkbox"/> This sheet was received with the international application Authorized officer 	For International Bureau use only <input type="checkbox"/> This sheet was received by the International Bureau on: Authorized officer
---	--

PATENT CLAIMS

1. An enzyme exhibiting aminopeptidase activity derived from a fungal microorganism, which enzyme has an apparent molecular weight (M_w) of 35 kDa determined by SDS-page.
2. The enzyme according to claim 1, having an estimated isoelectric point (pI) in the range of about 4.9.
- 10 3. The enzyme according to claims 1 to 2, wherein the enzyme in the precursor-form has an estimated molecular weight of about 41 kDa.
4. The enzyme according to claim 3, wherein the enzyme in
15 the precursor-form include a secretion signal.
5. The enzyme according to any of claims 1 to 4, derivable from a filamentous fungus or a yeast.
- 20 6. The enzyme according to claim 5, derivable from a filamentous fungus, such as *Aspergillus*, in particular *A. oryzae*, Especially *A. oryzae* A01568, or *Trichoderma*, *Penicillium*, *Fusarium* or *Humicola*.
- 25 7. The enzyme according to any of claims 1 to 6, which enzyme comprises or is comprised in the partial amino acid sequence shown in SEQ ID No. 6 or an analogue of said sequence, the partial amino acid sequence shown in SEQ ID No. 7 or an analogue of said sequence, and/or the partial amino
30 acid sequence shown in SEQ ID No. 8 or an analogue of said sequence, and/or the partial amino acid sequence shown in SEQ ID No. 9 or an analogue of said sequence, and/or the partial amino acid sequence shown in SEQ ID No. 10 or an analogue of said sequence and/or the partial amino acid sequence shown in
35 SEQ ID No. 11 or an analogue of said sequence.

8. The enzyme according to any of claims 1 to 7, which n-
zyme comprises or is comprised in the amino acid sequence
shown in SEQ ID No. 2 or an analogue of said sequence.

5 9. The enzyme according to any of claims 1 to 8, which is
immunologically reactive with an antibody raised against the
purified aminopeptidase shown in SEQ ID No. 2 derived from
Aspergillus oryzae, A01568.

10 10. The enzyme according to any of claims 1 to 9, which en-
zyme comprises in the range of 35 to 45% non-polar amino
acids, preferably between 37 to 41%, and/or in the range of
30 to 40% polar amino acids, preferably between 33 to 37%,
and/or in the range of 10 to 20% acidic amino acids, prefer-
15 ably between 12 to 16%.

11. The enzyme according to any of claims 1 to 10, which
enzyme comprises in the range of 7 to 17% acidic amino acids,
preferably between 10 to 14%.

20

12. A DNA construct comprising a DNA sequence encoding an
enzyme exhibiting aminopeptidase activity, which DNA sequence
comprises

a) the aminopeptidase encoding part of the DNA sequence shown
25 in SEQ ID No. 1, and/or the DNA sequence obtainable from *E.*
coli DSM 9965, or

b) an analogue of the DNA sequence shown defined in a), which

30 i) is homologous with the DNA sequence shown in SEQ ID No.
1 and/or the DNA sequence obtainable from *E. coli* DSM
9965,

or

ii) hybridizes with the same oligonucleotide probe as the
35 DNA sequence shown in SEQ ID No. 1 and/or the DNA sequ nce
obtainable from *E. coli* DSM 9965, or

iii) encodes a polypeptide which is homologous with the polypeptide encoded by a DNA sequence comprising the DNA sequence shown in SEQ ID No. 1 and/or the DNA sequence obtainable from *E. coli* DSM 9965, or

5

iv) encodes a polypeptide which is immunologically reactive with an antibody raised against the purified aminopeptidase encoded by the DNA sequence shown in SEQ ID No 1 derived from *Aspergillus oryzae* A01568 and/or obtainable
10 from *E. coli*, DSM 9965.

13. The DNA construct according to claim 12, comprising the partial DNA sequences shown in SEQ ID No. 3, and/or the partial DNA sequences shown in SEQ ID No. 4, and/or the
15 partial DNA sequences shown in SEQ ID No. 5.

14. The DNA construct according to any of claims 12 to 13, in which the DNA sequence is obtainable from a fungal microorganism, such as a filamentous fungus or a yeast.

20

15. The DNA construct according to claim 14, in which the DNA sequence is obtainable from a strain of *Aspergillus*, such as *Aspergillus oryzae*, in particular from the deposited *Aspergillus oryzae*, ATCC 20386, or *Trichoderma*, *Penicillium*,
25 *Fusarium*, *Humicola* or *E. coli* DMS 9965.

16. The DNA construct according to claim 30, in which the DNA sequence is isolated from or produced on the basis of a nucleic acid library of *Aspergillus oryzae*, A01568.

30

17. A recombinant expression vector comprising the DNA construct according to any of claims 12 to 16.

18. A cell comprising a DNA construct according to claims 12
35 to 16 or a recombinant expression vector according to claim 17.

19. The cell according to claim 18, which is a eukaryotic cell, in particular a fungal cell, such as a yeast cell or a filamentous fungal cell.

5 20. The cell according to claim 19, wherein the cell belongs to a strain of *Aspergillus*, in particular a strain of *Aspergillus niger* or *Aspergillus oryzae*, a strain of *Saccharomyces*, in particular *Saccharomyces cerevisiae*, *Saccharomyces kluyveri* or *Saccharomyces uvarum*, a strain of *Schizosaccharo-*
10 *myces* sp., such as *Schizosaccharomyces pombe*, a strain of *Hansenula* sp. *Pichia* sp., *Yarrowia* sp. such as *Yarrowia lipolytica*, or *Kluyveromyces* sp. such as *Kluyveromyces lactis*.

21. The cell according to claim 20, wherein the cell belongs
15 to a strain of *Aspergillus*, in particular a strain of *Aspergillus niger* or *Aspergillus oryzae*.

22. A method for producing an enzyme exhibiting aminopeptidase activity, which method comprises cultivating a cell
20 according to any of claims 18 to 21 in suitable culture medium under conditions permitting the expression of the DNA construct according to any of claims 12 to 16 or expression vector according to claim 17, and recovering the enzyme from the culture.

25

23. An enzyme preparation useful for reducing bitter taste of proteins or protein hydrolysates for foodstuff, which preparation is enriched with an enzyme exhibiting aminopeptidase activity of any of claims 1 to 11.

30

24. The enzyme preparation according to claim 23, which preparation is enriched with a factor of between 1.1 and 10, preferable between 2 and 8, especially between 4 and 6.

35 25. The enzyme preparation according to claims 23 and 24, which additionally comprises at least one other enzyme activity, including a cellulase, a hemicellulase, a pento-

sanase, a lipase, a peroxidase, an oxidase, a laccase, a xylanase, a peptidase, and an endo-protease.

26. A bread-improving or a dough-improving composition
5 comprising an enzyme exhibiting aminopeptidase activity according to any of claims 1 to 11.

27. The bread-improving or dough-improving composition according to claim 26 which further comprises an amylolytic
10 enzyme, selected from the group comprising α -amylase, β -amylase, maltogenic α -amylase, acid stable amylase, 1,6-pullulanase and amyloglucosidase.

28. The bread-improving or dough-improving composition according to claim 26 and 27, which further comprises another
15 enzyme such as a cellulase, a hemicellulase, a pentosanase, a lipase, a peroxidase, an oxidase, a laccase, and a xylanase.

29. The bread-improving or dough-improving composition according to any of claims 26 to 28, which further comprises
20 another bread or dough improving agent.

30. A method of preparing a baked product from a flour dough, which method comprises, in the dough making process, to add
25 an enzyme exhibiting aminopeptidase activity according to any of claims 1 to 11 to the dough or dough ingredients and subject the resulting dough to baking under suitable conditions.

30 31. The method of preparing a baked product from a flour dough according to claim 30, which method comprises, in the dough making process, further to add an amylolytic enzyme to the dough or dough ingredients and subject the resulting dough to baking under suitable conditions.

35

32. The method according to claim 31, in which the amylolytic enzyme is selected from the group consisting of α -amylase, β -

amylase, maltogenic α -amylase, acid stable amylase, 1,6-pul-lulanase, and amyloglucosidase.

33. The method according to any of claims 11-18, in which an-
5 other enzyme such as a cellulase, a hemicellulase, a pentosa-
nase, a lipase, a peroxidase, an oxidase, a laccase, an amy-
lase, a xylanase is added to the dough or dough ingredients.

34. The method according to any of claims 30-34, in
which the enzyme according to any of claims 1 to 11 is added
10 in an amount corresponding 30 to 1000 LAPU, preferably 50 to
500 LAPU, especially 80 to 300 LAPU, such as about 100 LAPU
per kg of flour.

35. The method according to any of claims 30-34, in which the
15 enzyme(s) is/are added in the form of a bread-improving or
dough-improving composition as defined in any of claims 26-
29.

36. A method of preparing a frozen dough, which method com-
20 prises, in the dough making process, to add an enzyme exhi-
biting aminopeptidase activity according to any of claims 1
to 11 to the dough or dough ingredients and subject the re-
sulting dough to freezing under suitable conditions.

25 37. The method according to claim 36, in which an amylolytic
enzyme is added together with the enzyme exhibiting aminopep-
tidase activity according to claims 1 to 11.

38. The method according to any of claims 36 and 37, in which
30 the enzyme(s) is/are added in the form of a bread-improving
or dough-improving composition as defined in any of claims
26-29.

39. A baked product or a dough prepared by the method accord-
35 ing to any of claims 30-38.

40. A pre-mix for dough comprising an enzyme exhibiting aminopeptidase activity according to any of claims 1 to 11 or a bread-improving or dough-improving composition according to any of claims 26-29.

5

41. Use of the enzyme exhibiting aminopeptidase activity according to any of claims 1 to 11 or a composition according to any of claims 26 to 29 for improving the flavour of a baked product.

10

42. Use of the enzyme exhibiting aminopeptidase activity according to any of claims 1 to 11 or a composition according to any of claims 26 to 29 for improving the dough stickiness of a baked product.

15

43. Use of the enzyme exhibiting aminopeptidase activity according to any of claims 1 to 11 or a composition according to any of claims 26 to 29 for improving the crumb structure of a baked product.

20

44. Use of the enzyme exhibiting aminopeptidase activity according to any of claims 1 to 11 or a composition according to any of claims 26 to 29 for improving the crust colour of a baked product.

25

45. Use of the enzyme exhibiting aminopeptidase activity according to any of claims 1 to 11 or an enzyme preparation according to any of claims 23 to 25 for proteins or protein hydrolysates for foodstuff

30

46. The use according to claim 45, for debittering proteins or protein hydrolysates for foodstuff.

47. The use according to claims 45 and 46, wherein the protein or protein hydrolysate to be hydrolysed is of animal origin, such as casein or whey protein.

48. The use according to claim 47, wherein the foodstuff is cheese.

49. The use according to claims 45 and 46, wherein the protein or protein hydrolysate to be hydrolysed is of vegetable origin, such as soy protein.

50. The use according to claim 49, wherein the foodstuff comprises cocoa.

10

51. Use of the enzyme exhibiting aminopeptidase activity according to any of claims 1 to 11 or an enzyme preparation according to any of claims 23 to 25 for cleaning contact lenses.

15

52. Use of the enzyme exhibiting aminopeptidase activity according to any of claims 1 to 11 or an enzyme preparation according to any of claims 23 to 25 for brewing.

1/1




Figure 1

Lanes 1: Molecular weight marker.

Lane 2: Non-transformed *Aspergillus oryzae* A01560

Lanes 3 and 4: pA3EXP3/1 transformant (5 and 10 µl)

Lanes 6, 7 and 8: *Aspergillus oryzae* A01568

Lanes 10: A transformant using the same expression construct as for pA3EXP3/1 without aminopeptidase activity.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK 96/00104

A. CLASSIFICATION OF SUBJECT MATTER		
IPC6: C12N 9/48 According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols)		
IPC6: C12N		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
SE,DK,FI,NO classes as above		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)		
MEDLINE, BIOSIS, WPI, WPIL, US PATENTS FULLTEXT, CA, SCISEARCH, FSTA		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Dialog Information Services, File 5, BIOSIS, Dialog accession no. 8646033, Biosis no. 92111033, Matsuoka H et al: "Purification and Debittering Effect of Aminopeptidase II from Penicillium-Casei- colum"; & J Agric food Chem 39 (8). 1991. 1392-1395 --	1-52
X	WO 9426882 A1 (QUEST INTERNATIONAL B.V.), 24 November 1994 (24.11.94), page 12, line 4 - line 12; page 13, line 4 - line 27 --	1-52
X	US 5112812 A (ERNST-GUNNAR SAMUELSSON ET AL), 12 May 1992 (12.05.92), column 3, line 47 - line 54, claim 21 --	1-52
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input checked="" type="checkbox"/> See patent family annex.		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search		Date of mailing of the international search report
24 June 1996		04 -07- 1996
Name and mailing address of the ISA/ Swedish Patent Office Box 5055, S-102 42 STOCKHOLM Facsimile No. +46 8 666 02 86		Authorized officer Carolina Palmcrantz Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK 96/00104

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0257821 A1 (GENENCOR INC.), 2 March 1988 (02.03.88), page 3, line 30, claim 1 --	51
A	Dialog Information Services, File 351, WPIL, Dialog accession no. 009834356, WPI accession no. 94-114212/14, KIKKOMAN CORP: "Prepn. of solid koji for brewing soy sauce - comprises using solid koji contg. specified zinc ion content per total wt of koji ingredient"; & JP,A,6062793 940308 9414 (Basic) -- -----	52

INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK 96/00104

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.: 9, 12
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
see extra sheet
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK 96/00104

The wording "immunologically reactive with an antibody raised against..." does not define a property that is relevant in the context of the invention, as there is no direct link between the aminopeptidase activity and the immunological features (except for some unknown epitopes of the active site). Due to this vague definition claims 9 and 12 does not fulfil the requirements of PCT article 6 regarding clarity and conciseness.

The wording "homologous" of claim 12 is not considered to be clear and concise since it has not been specified to what extent the sequence is homologous with the DNA sequence/polypeptide corresponding to SEQ ID No. 3 or the DNA sequence obtainable from E.coli DSM 9965 (c.f. PCT article 6). It should be clear from the claim that the part(s) that encodes the alleged inventive features of the aminopeptidase is present in the analogue which is defined "homologous".

The wording "hybridizes with the same oligonucleotide probe" of claim 12 is not considered to be clear and concise since the part to which the oligonucleotide hybridizes with the analogue is not restricted to include the part(s) that encodes the alleged inventive features of the aminopeptidase (c.f. PCT article 6).

INTERNATIONAL SEARCH REPORT

Information on patent family members

01/04/96

International application No.

PCT/DK 96/00104

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO-A1-	9426882	24/11/94	NONE	
<hr/>				
US-A-	5112812	12/05/92	AU-B,B- 591230	30/11/89
			AU-A- 6834687	15/07/87
			AU-A- 6834787	15/07/87
			EP-A,A,B 0226221	24/06/87
			EP-A,A,B 0250501	07/01/88
			SE-T3- 0250501	
			FI-B- 89449	30/06/93
			IE-B- 59710	23/03/94
			JP-B- 8011039	07/02/96
			JP-T- 63502003	11/08/88
			JP-T- 63502004	11/08/88
			KR-B- 9403938	09/05/94
			WO-A,A- 8703785	02/07/87
			WO-A,A- 8703786	02/07/87
<hr/>				
EP-A1-	0257821	02/03/88	AU-A- 7628087	04/02/88
			JP-A- 63158520	01/07/88
			US-A- 4749511	07/06/88
<hr/>				

THIS PAGE BLANK (USPTO)